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ABSTRACT OF DISSERTATION

Understanding the Contributions of Alzheimer’s Disease & Cardiovascular Risks to
Cerebral Small Vessel Disease Manifest as White Matter Hyperintensities on Magnetic
Resonance Imaging (MRI)
Introduction: Alzheimer’s Diseases (AD) & cerebral small vessel disease associated with
cardiovascular risk factors (cSVD) frequently coexist, differentially affecting both imaging
and clinical features associated with aging and dementia. We hypothesized that Magnetic
Resonance Imaging (MRI) can be used in novel ways to identify relative contributions of
AD & cardiovascular risks to cSVD and brain atrophy, generating new biomarkers &
insights into mixed disease states associated with cognitive decline and dementia.
Methods: Three experiments were conducted to address the overarching hypothesis. First,
we visually rated the clinical MRI of 325 participants from a community-based crosssectional sample to elucidate the relative association of age, AD (visualized as hippocampal
atrophy) and cSVD (visualized as white matter hyperintensities; WMH) with global brain
atrophy in experiment 1. In experiment 2, we analyzed cross-sectional MRI scans from 62
participants from the University of Kentucky Alzheimer’s Disease Center (UKADC) with
available clinical data on cardiovascular risk and cerebrospinal fluid (CSF) beta-amyloid
levels as a marker of AD. Voxel wise regression was used to examine the association of
white matter hyperintensities with AD and/or cardiovascular risk (hypertension).
Experiment 3, examined longitudinal MRI changes in WMH volumes in 377 participants
from the Alzheimer’s Disease Neuroimaging Initiative 2 (ADNI 2). Subjects were
categorized into three groups based on WMH volume change, including those that
demonstrated regression (n=96; 25.5%), stability (n=72; 19.1%), and progression (n=209;
55.4%) of WMH volume over time. Differences in brain atrophy measures and cognitive
testing among the three group were conducted.
Results: In the first experiment, logistic regression analysis demonstrated that a 1-year
increase in age was associated with global brain atrophy (OR = 1.04; p = .04), medial
temporal lobe atrophy (MTA; a surrogate of AD) (OR = 3.7; p < .001), and WMH as
surrogate of cSVD (OR = 8.80; p < .001). Both MTA and WMH were strongly associated
with global brain atrophy in our study population, with WMH showing the strongest
relationship after adjusting for age. In the second experiment, linear regression as well as
mediation and moderation analyses demonstrated significant main effects of hypertension

(HTN; the strongest risk factor associated with cSVD) and CSF Aβ 1-42 (a surrogate of
AD) on WMH volume, but no significant HTN×CSF Aβ 1-42 interaction. Further
exploration of the independence of HTN and Aβ using a voxelwise analysis approach,
demonstrated unique patterns of WM alteration associated with either hypertension or CSF
Aβ 1-42, confirming that both independently contribute to WMH previously classified as
cSVD. Extending this work into a longitudinal model rather than focusing on purely crosssectional associations, we demonstrated that spontaneous WMH regression is common,
and that such regression is associated with a reduced rate of global brain atrophy (p =
0.012), and improvement in memory function over time (p = 0.003).
Conclusion: These data demonstrate that both AD and cSVD frequently coexist in the
same brain, contributing differentially to alterations in brain structure, subcortical white
matter injury, and cognitive function. These effects can be disentangled using MRI, and
while we currently lack therapeutic interventions to halt or reverse AD, the dynamic WMH
change evident in our data clearly suggests that the ability to reverse cSVD exists today.
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CHAPTER 1. INTRODUCTION
1.1 Introduction
Alzheimer’s Disease (AD) and Cerebral Small Vessel Disease (cSVD), are the two
major pathologies associated with cognitive decline dementia in the aging population
today.[1-4] They are often found to coexist in the same individual.[5, 6]
Recent data from several large-scale, community-based, autopsy cohorts have
demonstrated that mixed AD and vascular dementia (VaD) caused by cSVD is the norm
rather than the exception, especially as one ages. Trends for mixed pathology increase with
advancing age, reaching as high as 90% by the tenth decade of life.[7-10] It remains unclear
if the association of AD and VaD is mediated purely by age or if synergistic or additive
effects exist between these pathological mechanisms of degeneration allowing each disease
process to feed into the other.[9, 11, 12] Despite a high level of current interest in
elucidating mechanisms of synergistic interplay between AD and VaD, the field recognizes
that “pure” AD and “pure” VaD exist, suggesting that despite potential shared risk factors
and mechanisms, neither AD nor VaD are necessary or sufficient to cause the other.

1.2 Definition of Terms:
In this dissertation I am going to discuss several terms including cSVD, white
matter hyperintensity (WMH), cerebrovascular risk factors (CVR), AD and VaD.
Understanding the meaning attributed to each of these terms is critical for an indepth understanding of the work I will present.
cSVD is a term that is being used to define a syndrome of neuropathological, and
neuroimaging findings that are thought to be secondary to the effect of uncontrolled CVR
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(i.e. hypertension, hyperlipidemia, diabetes, smoking and atrial fibrillation) on perforating
cerebral arterioles and capillaries. These arterioles are essential to maintain a healthy brain
perfusion in the white matter in particular, which is enriched in small arterioles affected
most prominently by cSVD.[13]
cSVD can be visualized using structural magnetic resonance imaging (MRI).
Damage to the cerebral white matter that occur secondary to the cSVD can be seen using
both T2 and fluid attenuated inversion recovery (FLAIR) sequences on MRI, and appear
as areas of hyperintensities referred to as WMH. In addition, cSVD can be seen on T2,
FLAIR, and gradient echo sequences of the MRI as lacunar infarcts and cerebral
microbleeds that represent overt small vessel stroke and microhemorrhage, often related to
cerebral amyloid angiopathy (CAA) seen in conjunction with or independent of AD.[14,
15]
Late-life WMH largely represent cerebrovascular injury resulting from cSVD.[16]
In addition, WMH also occur in the pre-dementia stage of familial AD, including in those
with no appreciable CVR.[17, 18] It remains unclear whether these imaging findings
should be attributed to AD, cSVD, or to a combination of these pathological processes.
This question will be fully addressed in chapter 3.
There are five common mechanisms that lead to WMH:
I.

Ischemia:
A. Chronic ischemia: reduction in cerebral blood flow due to narrowing or
obstruction of small arteries and arterioles in subcortical and deep white matter
regions results in ischemia especially if those arterioles have only a single source
of blood.[19] Chronic ischemia leads to the death of oligodendrocytes contributing
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to myelinolysis.[13, 20, 21] This chronic ischemic injury will lead to the formation
of incomplete lacunar infarcts.[13] Incomplete lacunae are defined as areas of
selective neuronal or axonal necrosis. These lesions spare the vascular tissue and
the glial components of the affected areas.[22]
B. Acute ischemia: this will result from acute obstruction of cerebral small arteries
and arterioles. Acute ischemia results in the formation of complete lacunar
infarcts.[13] Deep white matter lacunes can occur in regions of WMH.
II.

Disruption of Blood-Brain Barriers (BBB): The most accepted non-ischemic
theory explaining WMH focuses on damage to the BBB. BBB breakdown results
in white matter damage caused by the toxic effect of extravasated proteins such as
fibrinogen, albumin and IgG and resultant inflammatory changes. Ischemic
changes may occur simultaneously with BBB damage, but the relative causality is
poorly understood.[13, 20, 21]

III.

Endothelial Damage: Both ischemia due to hypoperfusion and BBB disruption
can lead to the loss of endothelial integrity.[20] Also, toxic effects of homocysteine
on endothelial cells may contribute to endothelial damage.[23] As a result of
endothelial damage, nitric oxide is reduced, which negatively affects cerebral blood
flow through interference with autoregulatory mechanisms of cerebral white matter
small vessels.[24-26] Supporting evidence for this mechanism include observed
elevated levels of endothelial dysfunction markers such as intercellular adhesion
molecule 1 (ICAM1), thrombomodulin (TM), tissue factor (TF) and tissue factor
pathway inhibitor (TFPI).[27]
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IV.

Amyloid β: The Aβ deposition and level correlates with the severity of
arteriosclerotic disease.[20] Cerebral Amyloid Angiopathy (CAA) is characterized
by the accumulation of Aβ protein in the walls of small to medium sized blood
vessels and capillaries. In severe CAA, blood vessels’ walls may be damaged
causing leakage of blood into the surrounding brain tissue.[13] CAA was found to
be associated with intracerebral hemorrhage, and subcortical white matter injury,
and can be commonly seen in elderly subjects with Alzheimer’s disease, Down’s
syndrome and cSVD.[28, 29]

V.

Genetics: Many genetic risk factors may play a role in cSVD such as cerebral
autosomal

dominant

arteriopathy

with

subcortical

infarcts

and

leukoencephalopathy (CADASIL).[21] Many other hereditary diseases lead to
cerebral small vessel disease, including cerebral autosomal recessive arteriopathy
with subcortical infarct and leukoencephalopathy (CARASIL), Fabry’s disease,
hereditary extensive vascular leukoencephalopathy (HEVL), and mitochondrial
encephalopathy with lactic acidosis and stroke-like episodes (MELAS).[13]
Furthermore, ABCC9 Hippocampal Sclerosis-Aging risk genotype has been found
to be associated with a reduction in the cerebral blood flow.[30] Finally, APOE ԑ4
was found to have a role in the microvascular changes of the brain that ultimately
lead to arteriolosclerosis.[31] There is a strong association between the APO E ԑ4
genotype and atherosclerosis in addition to cerebral blood vessel structural changes
such as amyloid angiopathy (due to increased Aβ deposition). The latter is found to
be associated with increased risk of white matter injury. The ultimate associated
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effect of APO E ԑ4 is decreased cerebral blood flow which results in ischemic
damage to vulnerable areas and cognitive decline.[32]
It is important to note that WMH can be seen in several other neurological diseases
such as multiple sclerosis,[33] posterior reversible encephalopathy syndrome,[34]
dysmyelinating diseases such as metachromatic leaukodystrophy,[35] and epilepsy,[36] as
well as in a variety of other infectious, inflammatory or neoplastic disease states. However,
such diseases are rare in the aging population in contrast to AD and cSVD which are quite
common. As such, WMH resulting from both AD and cSVD are the focus of our
dissertation.[17, 37]
AD is a widely used abbreviation for Alzheimer’s disease, which is a clinical
syndrome of progressive cognitive impairment and functional decline over a period of 810 years.[38, 39] In this dissertation, “AD pathology” will be defined using different
imaging and cerebrospinal fluid (CSF) markers. Medial temporal lobe atrophy (MTA) is
one of the most commonly used surrogate imaging markers for AD that can be visualized
best on coronal T1-weightedMRI images.[40] Recently, young patients with familial AD
were found to have more WMH on the posterior part of the brain, which may prove useful
as an additional imaging marker for AD.[17, 18] In addition, CSF amyloid beta (Aβ) levels
and Aβ-PET imaging can be also used as biomarkers for AD.[41]
Finally, it is important to explain the stages or progression of cognitive decline for
both AD and VaD in their “pure forms”, while recognizing that conclusions arising from
the existing literature may in many cases be derived from “mixed” rather than “pure”
pathologic disease states.
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VaD refers to an impairment of memory resulting in functional decline secondary
to cerebrovascular disease including cSVD.[42, 43] Clinical VaD can be divided into three
stages: 1) the preclinical stage has been described by Hachinski V.C. et al.,[44] as the stage
wherebrain damage occurs but without significantcognitive impairment, 2) the mild
cognitive impairment stage (MCI) is characterized by cognitive impairment with intact
Activities of Daily Living (ADL), 3) A Major Neurocognitive Impairment stage (defined
in the DSM-V), also recognized as the stage of dementia with decline in ADL.[45]
It is widely recognized that at the stage of advanced dementia, the brain has suffered
significant irreversible injury. As such, the field has moved towards earlier detection of
disease. Targeting, diagnosis and secondary prevention in the preclinical and MCI stages
is reasonably believed to be the best way to impact the disease process. In addition,
focusing on these early predementia stages of VaD allows planning for future needs for
both the patient and potential caregiver.[46] As such the focus of this dissertation and the
patient population studied largely focus on the preclinical and MCI stages of VaD.
Preclinical VaD is a term used to describe a state of normal cognition characterized
by early pathological changes of the cardiovascular system that are likely to lead to future
cSVD and clinical cognitive decline if allowed to continue to progress.[47]
The Framingham Risk Score (FRS) is used as a primary risk assessment tool for
cerebrovascular disease in asymptomatic healthy persons, as well as risk for cognitive
decline in those that are already symptomatic. Traditional CVR included in the FRS are
patient age, history of smoking and HTN, total serum cholesterol and high density
lipoprotein (HDL). Ten-year risk scores are expressed as a percentage stroke risk. A
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percentage between 0-10% is considered low risk, moderate risk falls between 11-20%,
and a high risk occurs when the ten-year risk is greater than 20%.[48]
MCI was developed as a concept to identify individuals at risk for the future
development of dementia. While initially developed as a construct to identify prodromal
Alzheimer’s disease dementia, the concept was broadened in 2004 to include
categorization based on cognitive domain involvement in order to predict the underlying
pathologic event responsible for the cognitive decline which may include pathologic
disease states disparate from Alzheimer’s alone, such as VaD.[49] These criteria are as
follows:
I. Global cognition should be preserved;
II. A cognitive deficit that is reported by self or caregiver with an evidence of such
complaint; (typically set at > 1.5 s.d. below age and education adjusted means)
III. Not demented by DSM-IV criteria;
IV. No, or minimal functional impairment.
This schema includes diagnosis of MCI into four major subtypes based on presence
vs. absence of memory involvement and further on the presence of involvement of a single
vs. multiple cognitive domains as described below in Figure 1.1.
The schema in Figure 1.1 has been developed to allow clinical determination of the
potential causes for the cognitive impairment noted. Practical application of the schema for
predicting underlying cause of cognitive decline is illustrated in Figure 1.2. It should be
noted that this diagnostic schema has not been fully validated and ongoing work is needed
to fully delineate the specific features of MCI due to specific underlying or mixed
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Figure 1.1 Diagnosis of Mild Cognitive Impairment.
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Figure 1.2 Mild Cognitive Impairment subtypes.

pathologies. This is a practical working clinical and conceptual classification at the present
time.

1.3 The Role of Imaging in the Diagnosis of AD & cSVD:
Much work has gone into describing the unique cognitive sequelae associated with
both prototypical AD and VaD secondary to cSVD (Table 1.1). Descriptions however are
often contradictory or overlapping given the extent of shared pathology in each of these
disease states. Prototypical early changes in AD include deficits in episodic memory
followed by later decline in language, executive, and visuospatial function.[50]
Descriptions of prototypical changes in VaD have been more complex as a result
of the pathologic and neuroanatomic heterogeneity inherent in this disease state. Cognitive
9

Table 1.1 Specific cognitive domain involvement associated with aging and/or
cerebrovascular risk factors across cohort studies.

Study

CVD risk
factor studied

Design

Affected cognitive
domain

Type 2 diabetes mellitus,
hypertension, dyslipidemia and
obesity [51].

Type-2 DM,
HTN, HLD
and Obesity

Systematic
Review

memory,
processing speed
and cognitive
flexibility

The cognitive correlates of white
matter abnormalities in normal
aging [52]

Aging

The Aging Brain [53]

Aging

Review

Delay recall of
verbal memory

Cognitive impairment in heart
failure [54]

Heart Failure

Systematic
review

Memory,
processing speed
and attention

Cognitive outcomes after acute
coronary syndrome [55]

Myocardial
infarction

Prospective
population
based cohort
study

Mostly memory
and language.
Executive function
was affected to a
lesser extent

Atrial Fibrillation Is an
Independent Determinant of Low
Cognitive Function [56]

Atrial
Fibrillation

CrossSectional
study

Memory,
processing speed
and possibly
executive function

Homocysteine and the brain in
midadult life: Evidence for an
increased risk of leukoaraiosis in
men [57]

Homocysteine

CrossSectional
study

Verbal memory

10

Quantitative Executive functions
review
(explained by
reduced volume of
prefrontal cortex),
processing speed
and working
memory.

domain involvement can vary due to the primary vascular insult contributing to VaD, such
as multi-infarct dementia, isolated strategic infarcts, and cSVD. Of these varied causes, the
latter may have a more uniform pattern of cognitive impairment given the more uniform
distribution of vascular lesions between cases that conform largely to end arterial
watershed zones in the subcortical white matter. In VaD related to cSVD, a decline in
executive function may be the earliest clinical sign of disease although memory can
frequently be affected again creating confusion in distinguishing AD from VaD or mixed
dementia on the basis of clinical presentation alone.[50]
In general, many believe that VaD patients tend to have relatively preserved verbal
long term memory in the setting of markedly impaired executive function compared to the
reverse seen for AD patients in the early stages of disease.[58] We do note however that as
the disease progresses to the moderate to severe stages a distinction based on clinical
presentation becomes less clear.[59]
Given the difficulty in distinguishing AD from cSVD or mixed dementia clinically,
the field has largely relied on imaging evidence for either AD or cSVD changes to diagnose
specific or mixed disease states. Advances in neuroimaging techniques that can guide the
diagnosis of dementia has revolutionized the field. Such techniques include structural,
functional, and molecular neuroimaging.
Structural neuroimaging, such as routine MRI and CT-scan, can delineate
anatomical structure of the brain due to the high spatial resolution of these biomarkers,
allowing and evaluation of specific tissue injury as well as patterns of cerebral atrophy that
are specific for distinct disease states. Functional neuroimaging including FluoroDeoxyglucose Positron Emission Tomography (FDG-PET), functional MRI (fMRI) and
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Single Positron Emission Computed Tomography (SPECT), can delineate metabolic
activity in specific brain regions that are affected in distinct disease states.[60, 61]
Molecular imaging techniques such as Amyloid-PET, tau-PET, DaTscan (Dopamine
Transporter (DAT) used with SPECT), and many other techniques and development can
actually visualize the cellular, molecular, and pathologic changes that are distinct between
subtypes of dementia. The following section focuses on these imaging advances and their
role in accurately diagnosing and tracking disease progression in AD, VaD, and mixed
dementia. An overview of currently used imaging modalities and specific findings in AD
and VaD is presented in Table 1.2.
The current American Academy of Neurology practice parameter on the diagnosis
of dementia requires the use of structural neuroimaging to evaluate non-neurodegenerative
contributors to dementia such as vascular injury, intrinsic brain abnormalities, neoplasm,
normal pressure hydrocephalus, brain contusions and other structural lesions that may be
causative of cognitive decline and dementia.[62] The practice parameter does not
specifically recommend one type of structural neuroimaging over another and yet each vary
in practical application and extent of data derived in order to facilitate identification of
underlying pathologic mechanisms responsible for any clinical cognitive decline seen in
AD. The most recent iteration of diagnostic criteria for AD, includes structural imaging as
a supportive biomarker that can demonstrate disease state specific neuronal injury, and
molecular imaging techniques such as amyloid-PET, as ancillary criteria for the diagnosis
of AD irrespective of the presence of comorbid CVD.[63]
CT-scans are primarily used to exclude other pathologies such as tumors and
strokes. In addition, measuring hippocampal atrophy is also possible using CT-scans by
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Table 1.2 Neuroimaging biomarker modalities and protocols that are commonly used for
the diagnosis and tracking of Alzheimer’s and cerebrovascular disease.
Technique

Protocol

Pathology studied

Characteristics

MPRAGE

Size and shape of brain
regions, tumors, atrophy

Demonstrates specific
structural abnormalities

FLAIR

WMH, hemorrage, CSF

Demonstrates evidence for
vascular injury

ASL

Blood perfusion

Identifies reduced perfusion in
both AD & cSVD

Oxygen concentration

Identifies coactivated brain
regions establishing functional
connectivity

BOLD (fMRI)
MRI

DTI

FA

Longitudinal water
molecule movement
inside the fibers

DM

average of water
diffusion in all
directions

ADC

The axial diffusion of
water
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C-PiB-PET

PET
18

F-amyloid tracers

18

SPECT

F-FDG

99m

Tc-ECD

Identifies disruted
Myelination of fiber tracts

Presence of cerebral Aβ

Ligand binds Aβ, 11C isotope
requires cyclotron near
facility, limiting broad use of
this agent

Presence of cerebral Aβ

Ligand binds Aβ, 18F isotope
stability allows more
widespread use of this agent

Glucose metabolism

Ligand is substrate for TCA
cycle glucose utilization

Blood perfusion

Identifies reduced perfusion in
both AD & cSVD
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specialists, however these techniques are inferior to the analysis afforded by MRI given its
ability to visualize the brain in multiple planes that are devoid of bony artifact.[64] CTscans can also identify overt areas of ischemic injury and provide evidence for subcortical
small vessel disease that could be responsible for cSVD or mixed disease.
Brain MRI is being used in most centers to guide the diagnosis of AD, with the
exception of use in patients with implanted or injury associated ferrous metal that would
preclude the use of a high field magnet.[65] MRI is essentially contraindicated in any
patient with an implanted metallic device such as pacemaker, brain or spinal cord
stimulator, or implanted infusion pump. In addition, while the availability of MRI scanners
has increased dramatically over the last several decades there are still many smaller and
rural medical centers that do not have access to MRI for routine diagnostic purposes.
Brain MRI is the most widely used tool for the diagnosis of cSVD as recommended
by the STandard for ReportIng Vascular changes on nEuroimaging (STRIVE).[15] cSVD
is to some extent ubiquitous in VaD, irrespective of overt large vessel ischemic or
hemorrhagic stroke and is characterized by imaging findings including increased T2 signal
abnormalities in the subcortical white matter (WMH), lacunar infarcts, small subcortical
infarcts, and cerebral microbleeds). There is a general consensus that such T2 signal
abnormalities affecting more than 25% of the white matter are indicative of cSVD.[66]
Figure 1.3 illustrates MRI characteristics that can discriminate between AD and cSVD.
T1-weighted Magnetization Prepared Rapid

Acquisition Gradient

Echo

(MPRAGE) imaging sequence has high special resolution, affording 3-dimensional
reconstructions of the brain that can be visualized in any plane, that can evaluate changes
in cortical sulci and atrophy in hippocampus, parahippocampal gyrus, entorhinal cortex,
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Figure 1.3 Descriptive structural imaging findings in Alzheimer’s (AD) and vascular
(VaD) or mixed dementia.
Panel A demonstrates typical medial temporal lobe atrophy seen in AD (red arrows). Panel
B illustrates typical white matter hyperintensities (red arrow head), lacunar infarcts (blue
arrow head), and cerebral atrophy (green arrow head) associated with VaD or mixed
dementia. Note: global cerebral atrophy may be seen in both AD and VaD and does not
distinguish these disease states.

posterior cortex, subcortical nuclei and amygdala, which are affected earliest in the course
of disease for AD patients.[67, 68] T1-weighted sequences in particular, can aid the
clinician and researcher in estimating Medial Temporal lobe Atrophy (MTA) as an early
neuroimaging marker of AD.[69] Semi-quantitative visual rating scale such as the
Scheltens’ scale, can be easily taught and assessed with routine clinical imaging in either
two-dimensional or 3-dimensional sequences.[70] Evaluation of medial temporal lobe
atrophy is best performed in the coronal plane which allows more accurate visualization of
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medial temporal lobe volumes that are not affected by tangential slicing of these structures
as can occur with axial and/or sagittal acquisitions. In addition, there are a number of
automated and semi-automated post acquisition processing software programs that can
provide voxel by voxel volumes allowing quantitative assessment of these and other
discrete structures within the brain. Several of these software programs, such as FreeSurfer,
are open access and represent the state-of-the-art tools for researchers in the field. Such
automated segmentation software can provide accurate volumetric measurements that can
be used to estimate diagnostic probabilities for the presence of AD pathology in the
antemortem state.
T2-weighted imaging is highly sensitive to tissue water content changes that are a
marker for ischemic cerebrovascular disease injury. FLAIR imaging sequences null the
signal derived from pure fluid compartments such as the ventricular system, allowing
accurate evaluation of periventricular and cortical surface hyperintensities that would not
be seen in routine T2 imaging sequences.[71, 72] These developments have dramatically
improved our ability to assess contributions of vascular injury in relation to the clinical
presentation of each unique patient imaged. There are many sophisticated methods to
quantify the volume of WMH using FLAIR sequence of the brain MRI (Figure 1.4).
However, simple visual rating such as Fazekas’ scale [14] can be used by clinicians and
researchers to estimate the WMH burden and guide the diagnosis of cSVD in routine
clinical practice.
Diffusion Tensor Imaging (DTI) sequence can evaluate the integrity of axonal
pathways forming large fiber tracts that connect often remote brain structures and regions.
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Figure 1.4 Sophisticated WMH volume quantification.
Upper row: Segmentation steps to classify brain grey matter (GM), white matter (WM),
and CSF. A. GM segment, B. first WM segment, C. second WM segment, D. CSF segment,
E. total WM (C2+C3). Lower row: Extraction of white matter (WM) hyperintensities for
quantitation. F. FLAIR image, G. extracted FLAIR WM image, H. result of thresholding
FLAIR WM image (F), I. Gaussian smoothed extracted WM hyperintensities. WM
hyperintensity volume is volume sum of voxels in I.

DTI can detect the microstructural changes in AD in the early stage before these changes
appear anatomically.[73, 74] DTI parameters that are typically measured include Fractional
Anisotropy (FA), Axial Diffusion Coefficient (ADC) and Mean Diffusivity (MD) (Figure
1.5 A and B). These parameters are based on our understanding of water movement in
relation to myelinated parallel fiber pathways. Typically, water molecules move (diffuse)
more rapidly in the fiber tracts longitudinally parallel to the axonal wall compared to more
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slowly diffusing water molecules perpendicular to the wall. FA tracks the water molecule
movement inside and parallel to the fibers.[75]
Figure 1.5 A representative brain MRI of 80 years old female showing DTI and ASL.
A. DTI-FA (highest FA is brightest), B. DTI-MD and C. PASL-Perfusion images (pseudo
color, blue lowest and red highest perfusion).

For AD patients FA decreases throughout many pathways in the superior-inferior part of
the brain.[76, 77] MD reflects the average of molecule diffusion in all directions per voxel
depending on the membrane or barrier permeability of the axon and is elevated in AD
patients. ADC demonstrates the diffusion of molecules in the axial direction of the
fiber.[78] ADC reductions are associated with axonal damage and increases in AD
subjects.[79] These changes appear quite distinct in both neuroanatomic specificity as well
as extent in AD vs. cSVD subjects. Compared to the WMH quantification, DTI measures
are less vulnerable to error attributed to using one’s judgment and manual editing when
using automated and semi-automated quantitative methods.[80] Haller et al. reported that
DTI and more specifically the MD measures represent the most accurate imaging
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biomarker for cSVD, even in the presence of AD.[80] Similarly, another study found that
DTI measures were effective in distinguishing between early stage AD and cSVD.[81] It
remains uncertain if overlap in DTI measures between AD and cSVD can reliably detect
mixed disease states.
MRI can also be quite useful in detecting Cerebral Microbleeds (CMB), which are
frequently related to the presence of cerebral amyloid angiopathy. CMBs can be visualized
using MRI T-2 echo gradient, and are visualized as small hypointensities range in size from
2-10 mm. CMB can be seen in up to two thirds of AD and cSVD patients and so may be
less useful in distinguishing between AD, cSVD, and mixed dementia than other
modalities.[66, 82] In extreme cases however brain injury secondary to cerebral amyloid
angiopathy and widespread CMBs can be a major contributor to cognitive decline that can
involve both AD as well as cerebrovascular tissue injury.
Amyloid Positron Emission Tomography (Amyloid-PET) is the only imaging
technique that can visualize amyloid deposition in the living brain. Multiple amyloid-PET
tracers have been developed for research purposes and have eventually garnered FDA
approval including Pittsburg Compound B (PiB), Florbetapir, Florbetaben, and
Flumetamol. The former made the availability of the amyloid PET difficult due to its C-11
component’s short half-life. This issue was resolved using other longer half-life
compounds such as 18F (for example Florbetapir, Florbetaben, and Flumetamol), which
made amyloid-PET widely available.[66]
Amyloid PET scans are approved by the FDA for the detection of cerebral amyloid
deposition and are not specific to any individual disease state. They can be useful in
differentiating dementia such as AD from other forms of dementia that do not include
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amyloid deposition asa pathologic feature such as Frontotemporal Dementia (FTD).[83,
84] The specificity of amyloid PET scans for Alzheimer’s disease is low and positive scans
are also frequently seen in cases of Dementia with Lewy Bodies (DLB).[85, 86] Similarly,
cases with mixed dementia were found to have a positive amyloid PET scan although this
is related to the comorbid Alzheimer pathology rather than direct visualization of vascular
amyloid.[87] While the PET ligands do bind vascular amyloid, this is found in much lower
abundance in the brain than plaque associated amyloid and it is unclear how the presence
or absence of cerebral amyloid angiopathy may influence the PET scan results. It should
also be noted that amyloid PET scans are positive in about 20-30% of people with normal
cognition,[88] and are used to detect the pre-clinical stage of AD.[89] This has opened up
new possibilities for secondary prevention trials in the area of AD.
Functional MRI (fMRI) can detect oxygen consumption in specific brain regions
during rest and activity dependent stimulation by measuring the ratio of oxy- to deoxyhemoglobin. Blood-Oxygen-Level Dependent contrast imaging (BOLD) can demonstrate
abnormalities in the hippocampus, inferior parietal lobe, medial temporal lobe and
cingulate cortex in AD that may provide clues to a pure and/or mixed state.[90, 91] Work
investigating BOLD signal changes in subjects with cerebrovascular disease can produce
heterogeneous results again secondary to the heterogeneity of pathologic cause and neuro
anatomic involvement seen in cSVD.
Metabolic activity in the brain can also be visualized using Fluoro-Deoxyglucose
Positron Emission Tomography (FDG-PET). Radiolabeled glucoses up taken in
metabolically active tissues (mainly synapses in the brain), leading to increased signal in
such regions. In AD patients, FDG-PET typically shows a decrease in glucose metabolism
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localized to the superior and posterior temporal lobe in addition to the parietal lobe with
the medial portion of it being affected earlier in AD.[89, 92] FDG-PET results can be
variable again in cSVD, and lack specificity for this disease entity.
Single-photon emission computed tomography (SPECT) is sensitive to blood
perfusion (hypoperfusion) and chemical changes in the brain [93] and it could
prognosticate the change of MCI to AD early. [73]

99m

Tc-ethylcysteinate dimer (99mTc-

ECD) is commonly used with SPECT for cerebral blood perfusion imaging.[94] Patients
with early stages of AD usually have hypoperfusion or hypometabolism in the posterior
cingulate and precuneus,[66, 95] which then extended to the temporoparietal region
bilaterally that could be either symmetrical or asymmetrical. In general, SPECT is less
sensitive but more specific than FDG-PET for AD changes.[96, 97] While changes in
cerebral blood flow can be greatly influenced by cerebrovascular disease, specific patterns
of SPECT abnormalities cannot be predicted in subjects with cSVD.
Arterial Spin Labeling (ASL) is a noninvasive MRI sequence that allows evaluation
of tissue perfusion using magnetized protons within water molecules in the brain
circulatory system (Figure 1.5 C). AD patients’ ASL showed areas of hypoperfusion as
bilateral temporoparietal lobe similar to that seen in FDG-PET and SPECT. More
specifically inferior parietal, bilateral posterior cingulate and middle frontal gyrus showed
reduced perfusion in AD patients.[98, 99] ASL can be used to quantify the reduction of
cerebral blood perfusion in brain regions affected by microvascular disease.[100] ASL
consistently demonstrates a decrease in CBF in brain regions that have been affected by
microvascular change, apparent as increased T2 signal hyperintensities on FLAIR imaging
sequences. in contrast to AD, cSVD is associated with decreased perfusion and metabolism
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of the sensorimotor cortex and subcortical white matter with preservation of the association
cortices.[66]
Each neuroimaging technique can contribute information in unique ways that can
be used to support the clinical diagnoses of AD, VaD, or other forms of dementia not
addressed in this thesis (see Table 1.1). Combining more than one technique may provide
more details about the future progression or prediction of the underlying disease state than
can be afforded through the use of a single imaging modality or fluid biomarker alone. For
instance, CSF results combined with other imaging techniques such as MRI, PET, SPECT
can provide a combination of structural, functional, and molecular information, which can
greatly enhance the specificity of clinical diagnoses and can be useful for differentiating
AD from other causes of dementia such as cSVD.[68, 73, 101]

1.4 CSF biomarkers of AD and cSVD
One of the most widely used biomarkers to diagnose AD is CSF, in which reduced
levels of Aβ have been found to be strongly associated with the accumulation of
parenchymal amyloid plaques. CSF Aβ levels have been found to be low even at the pre
AD stage of disease. However, absolute change in CSF Aβ levels are not correlated with
the rate of change in cognitive decline and/or the progression of dementia but instead
appear to represent a static state once the disease process is initiated.[102-104]
CSF can also be used to examine elevated levels of tau, total tau protein levels
and/or specific phosphorylated protein levels, which have a 79% specificity of identifying
subjects with AD. Combining CSF Aβ1-42 and tau levels increases the specificity for
identification of AD subjects to approximately 86%, and has proven to be
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the measurement of choice for diagnostic accuracy in determining an underlying pathologic
disease state of AD.[104]
There is still no consensus on whether specific CSF biomarkers may help identify
cSVD in either clinical or preclinical disease states.[105] Some studies showed have
demonstrated elevations in neurofilament light chain proteins, which presumably reflect
the extent of axonal damage secondary to cSVD.[105, 106] Other studies have shown that
cSVD subjects may have an elevated albumin CSF/serum ratio due to disruption of the
BBB.[105, 107] Both neurofilament light chain protein and the elevated albumin ratio
represent nonspecific, although potentially highly sensitive markers of cSVD, even in
normal control subjects.[108]

1.5 Hypotheses and Specific Aims:
Three experiments were developed as the core of this dissertation to address these
hypotheses:
1. Hypothesis 1: cSVD visualized as WMH on FLAIR imaging are related to global
cortical atrophy (GCA). (Increased WMH-> increased atrophy)
Specific Aim 1: Examine the relationship of cSVD, visualized as WMH on
FLAIR imaging, with GCA.
2. Hypothesis 2: AD is related to WMH seen on FLAIR imaging
Specific Aim 2: Investigate the association of the CSF Aβ (a surrogate of AD)
with WMH seen on FLAIR imaging. Further determine if the WMH associated
with AD vs. cSVD represent independent or dependent (additive or synergistic)
processes.
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3. Hypothesis 3: WMH are subject to dynamic change that may be related to
modulation by CVR and or to progressive AD changes.
Specific Aim 3: Determine the extent of dynamic WMH change overtime and
examine the association of WMH progression or regression with CSF Aβ
(surrogate for AD), and specific CVR.
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CHAPTER 2. BRAIN ATROPHY DETECTED BY ROUTINE IMAGING: RELATIONSHIP WITH
AGE, HIPPOCAMPAL ATROPHY, AND WHITE MATTER HYPERINTENSITIES

Summary:
Background and Purpose: Interpreting the clinical significance of moderate to severe global
cortical atrophy (GCA) is a conundrum for many clinicians, who visually interpret brain
imaging studies in routine clinical practice. In the absence of clinical signs of specific
neurological conditions, GCA may be attributed to normal aging, Alzheimer’s disease
(AD), or cerebral small vessel disease (cSVD). Understanding the relationships of GCA
with aging, AD, and cSVD is important for accurate diagnosis and treatment decisions for
cognitive complaints.
Methods: To elucidate the relative associations of age, white matter hyperintensities
(WMH), and medial temporal lobe atrophy (MTA), with GCA, we visually rated clinical
brain imaging studies of 325 participants from a community based sample. Logistic
regression analysis was conducted to assess the relations of moderate-to-severe GCA with
age, WMH, and MTA.
Results: The mean age was 76.2 (± 9.6) years, 40.6% were male, and the mean educational
attainment was 15.1 (± 3.7) years. Logistic regression results demonstrated that while a 1year increase in age was associated with GCA (OR=1.04; p=0.04), the effects of moderateto-severe MTA (OR=3.38; p<0.001) and moderate-to-severe WMH (OR=9.79; p<0.001)
showed much stronger associations with moderate-to-severe GCA in our study population.
Conclusions: Moderate-to-severe GCA should not be solely attributed to age when
evaluating clinical imaging findings in the workup of cognitive complaints. Moderate to
severe GCA is likely occur in the presence of AD or cSVD. Developing optimal diagnostic
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and treatment strategies for cognitive decline in the setting of moderate to severe GCA
requires an understanding of the contributors to moderate-to-severe GCA in the aging
population.

2.1 Introduction:
Interpreting the diagnostic significance of moderate to severe global cerebral
atrophy (GCA) is a conundrum for many clinicians, who visually interpret structural brain
magnetic resonance imaging (MRI) in routine clinical practice. Many clinicians attribute
GCA to the normal aging process.[109] Others may invoke degenerative processes such as
Alzheimer’s disease (AD), and yet others may relate these changes to cerebrovascular
insults and disease (CVD).[110, 111] Understanding the relationship of GCA with aging,
AD, and CVD would help inform accurate diagnosis and selection of appropriate
interventions to maintain brain volume, cognition, and function.
Irrespective of the cause of GCA, strong associations across multiple studies argue
that it is a reliable marker of cognitive and functional impairment seen in the aging
population.[112, 113] GCA can be readily identified using conventional imaging
techniques, such as MRI and computed tomography (CT) scans, and so is evaluated by
examining clinicians in virtually every case presenting with cognitive impairment.[114]
GCA can be reliably scaled on a semi-quantitative basis using standardized protocols [115]
and further quantified using volumetric analysis techniques. In routine clinical practice,
however, it is uncommon to use sophisticated volumetric techniques and instead qualitative
assessment prevails. Similarly, vascular changes—such as white matter hyperintensities
(WMH)[14, 116]—and medial temporal lobe atrophy (MTA) can be graded semiquantitatively using visual rating scales.[40] These features may also be analyzed using
26

more sophisticated quantitative volumetric measures, which again are not commonly relied
on by clinicians for making diagnostic or therapeutic decisions in routine clinical practice.
Potential contributors to GCA include age,[117] WMH associated with CVD,[110]
and AD.[111] Many studies have shown that the severity of GCA is associated with
increased age.[109, 117-121] Resnick et al. showed no detectable GCA over one year, but
reported 1.5 cubic centimeter increase in ventricular volume over the same period
longitudinal data analyses.[122] A subsequent analysis of two and four year follow-up data
from the cohort later revealed a significant association between GCA and age.[114] In
summary, although the literature is ambiguous, the hypothesis that GCA is associated with
age per se has become strongly fortified for many practicing clinicians and radiologists
MTA can be associated with both AD and to a lesser extent with normal aging.[119,
123] A recent report from Alzheimer’s Disease Neuroimaging Initiative (ADNI) showed
that absolute MTA two years after the baseline MRI scan ranges from a 1-7% loss of medial
temporal lobe volume in addition to a 10% increase in ventricular size.[124] While
ventricular changes may be readily discernable to the naked eye, MTA at a rate of only 17% per / year is difficult to detect in routine qualitative clinical evaluation of patient scans.
GCA has also been shown to be associated with CVD, and both share many
common risk factors.[110] Prior studies examining healthy participants found that
subcortical T2 signal changes in the white matter (i.e. WMH) were strongly associated with
GCA.[125-129] These studies suggested that the magnitude of the association between
WMH and GCA in cognitively intact subjects may be double that associated with aging in
the absence of WMH.[112] However, these findings have been disputed in several other
studies that reported no association between GCA and WMH.[130, 131]
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In order to further elucidate the relative associations of age, WMH (as a surrogate
for CVD), and MTA (as a surrogate for AD), with GCA, we examined MRI and CT with
semi-quantitative metrics of each from 325 participants in a community-based longitudinal
study of aging and cognition. Participants in the current study span the cognitive
continuum.

2.2 Methods:
2.1.1

Subjects:
Both MRI and CT scans were acquired during routine clinical evaluation of study

participants in the University of Kentucky Alzheimer Disease Center Cohort (n=325). 65%
of scans were MRI. Details of the recruitment and longitudinal evaluation of these
participants have been published previously.[132] This study was approved by the
University of Kentucky Institutional Review Board.
2.1.2

Visual rating of brain images:
Visual rating of clinical brain images was performed independently by three

physicians including a general neurologist (PP), neuroimaging specialist (CDS), and a
behavioral neurologist (GAJ) using the standardized visual rating scales described below.
Discrepant rating scores were adjudicated in a consensus conference including all three
raters.
Representative images from a young normal and elderly normal subjects with and
without imaging findings of WMH, MTA, and GCA are presented in Figure 2.1.
Global cerebral atrophy: GCA was visually rated on scale of (0-3) using T1 MRI
or CT structural images based on the semi-quantitative rating scale due to Pasquier and
colleagues.[115] The raw data were then dichotomized with scores of 0 and 1 considered
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Figure 2.1 Descriptive figure showing representative magnetic resonance imaging images.
From (A-C) a young normal, (D-F) an elderly subject without significant white matter
hyperintensity (WMH), medial temporal lobe atrophy (MTA), or global cerebral atrophy
(GCA), (G-I) an elderly subject with significant MTA and GCA without WMH, and (J-L)
an elderly subject with significant WMH and GCA without significant MTA.

(A), (D), (G), and (J) are axial fluid-attenuated inversion recovery images. (B), (E), (H),
and (K) are coronal T1 images. (C), (F), (I), and (L) are sagittal T1 images.
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as negative for significant atrophy (see figure 2.2 panel C and D), and scores of 2 and 3
considered as positive for moderate to severe atrophy (see figure 2.2 panel G, H, K and L).
Medial temporal lobe atrophy (MTA): MTA was rated based on the 5-point semiquantitative scale developed by Scheltens and colleagues [40] using T1 MRI or CT
structural images. The raw data were dichotomized as follows: scores of 0, 1 and 2 were
considered negative for significant atrophy, demonstrating only no or mild atrophy (see
figure 2.2 panel B), while scores of 3 and 4 were considered positive for moderate to severe
atrophy (see figure 2.2 panel F and J).
White Matter Lesions: We visually rated WMH using a modified Longstreth scale
[116] using CT scan or fluid attenuated inversion recovery (FLAIR) sequence of the MRI.
The Longstreth scale was compressed by mapping the 0-9 Longstreth score into a 1-4 scale,
using the mapping 1 = 0-2, 2 = 3-4, 3 = 5-6 and 4 = 7-8. The ends of the Longstreth scale,
0 and 9 are extreme values to account for extraordinary, rarely encountered instances of
either no periventricular hyperintensity rim at all (0) or extremely severe global white
matter hyperintensity exceeding even the severe 8 Longstreth rating (9). These extreme
ratings were incorporated for completeness into our 1 and 4 ratings respectively, but were
not in fact encountered in our images. The raw data were then dichotomized with scores of
1 and 2 considered as negative for significant WMH volume (see figure 2.2 panel A), and
scores of 3 and 4 considered as positive for moderate to severe WMH volume (see figure
2.2 panel E and I).
2.1.3

Statistical Analysis:
Descriptive statistics were used to summarize the study sample. A Spearman

analysis was conducted prior to multivariable analysis to assess the degree of correlation
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Figure 2.2 Descriptive figure showing the contribution of vascular damage (represented as
white matter hyperintensity; WMH) and Alzheimer’s Disease (represented as medial
temporal lobe atrophy; MTA) to global cerebral atrophy (GCA).

The upper row is an example of a subject with no-mild WMH on the fluid attenuated
inversion recovery (FLAIR) image (A) and MTA on the coronal T1 image (B). Note that
the subject with no-mild WMH and MTA has no-mild GCA as shown in the transverse and
sagittal T-1 image in the upper row (C and D respectively). The middle row is an example
of a subject with moderate-severe WMH on the FLAIR image (E) and MTA on the coronal
T1 image (F), which is associated with moderate-severe GCA seen on the transverse and
sagittal T-1 image (G and H respectively). The lower row represents a second example of
moderate-severe WMH on the FLAIR image (I) and MTA on the coronal T-1 image (J).
Note that this subject also has moderate-severe GCA as shown in the transverse and sagittal
T-1 image in the lower row (K, and L respectively).
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among the study measures. Simple and multivariate logistic regression models using
dichotomous measures for GCA (as described above) were performed to examine the
association with age, WMH, and MTA. A separate ordinal logistic regression model was
run using an ordinal measure of GCA (0-1 = no or mild GCA, 2 = moderate GCA and 3 =
severe GCA). The proportional odds assumption was checked with the Score test. Potential
two-way interaction between WMH and MTA in relation to GCA was included in the
adjusted models. Statistical analyses were performed using Stata 14.

2.3 Results:
Demographic and clinical features of the research participants are presented in
Table 2.1 The mean participant age was 76.2 years (± 9.6 years, range 41-96 years), 40.6%
were male, and the mean number of years of formal education was 15.1 years (± 3.7 years).
Spearman correlation analysis showed that age, WMH and MTA were all positively and
significantly correlated with GCA, with the strongest correlation between WMH and GCA
(rho=0.54) (table 2.2). In addition, WMH, MTA, and GCA severity were found to be
positively and significantly correlated with age in the Spearman correlation analysis (table
2.2).
Simple logistic regression models using the dichotomized GCA variable (GCA of
moderate-to-severe atrophy vs. no or mild atrophy) showed that the odds of having
moderate-to-severe GCA increased 7.5% with each one-year increase in age (Model 1,
table 2.3). Participants with moderate-to-severe MTA had 5.3 times the odds of moderateto-severe GCA than those with no or mild MTA (Model 2, table 2.3). Similarly, the odds
of having moderate-to-severe GCA were 13.6 times higher in participants with moderateto-severe WMH than those with no or mild WMH (Model 3, table 2.3).
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Table 2.1 Participant demographic, clinical, and imaging characteristics.
Participant Characteristics

Total

Age (mean ± SD)

76.2 ± 9.6

Sex (male n [%])

132 (40.6)

Education (mean ± SD)

15.1 ± 3.7

Cognitive Diagnosis
Normal n (%)

87(26.8)

Mild Cognitive Impairment n (%)

129 (39.7)

Dementia n (%)

109 (33.5)

Imaging Results
GCA (n [% of subjects with moderate-to-severe ])

198 (60.9)

MTA (n [% of subjects with moderate-to-severe])

115 (35.4)

WMH (n [% of subjects with moderate-to-severe])

155 (47.7)

SD = standard deviation; n = number of subjects; GCA = global cerebral atrophy; MTA =
medial temporal lobe atrophy; WMH = white matter hyperintensity burden.
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Table 2.2 Correlations among age (in years), white matter hyperintensity burden (WMH,
rated 1-4), medial temporal lobe (MTA, rated 0-4) and global cerebral atrophy (GCA, rated
0-3).
Age

MTA

WMH

GCA

rs

P

rs

P

rs

P

0.0000*

0.41

0.0000*

0.32

0.0000*

0.0000*

0.34

0.0000*

0.54

0.0000*

Age

--

0.23

MTA

--

--

0.29

WMH

--

--

--

GCA = global cerebral atrophy; MTA = medial temporal lobe atrophy; WMH = white
matter hyperintensity burden; rs = Spearman correlation coefficient.
*P <0.0001
In the multivariable logistic regression model, age remained significantly
associated with the risk of having moderate-to-severe GCA and showed that the odds of
having moderate-to-severe GCA increased 3.5% with each one-year increase in age, after
adjustment for WMH and MTA scores (Model 4, table 2.3). Furthermore, participants with
moderate-to-severe WMH had 9.76 times the odds of having moderate-to-severe GCA than
those with no or mild WMH. Additionally, subjects with MTA scores in the moderate-tosevere range had 3.47 the odds of moderate-to-severe GCA than those with no or mild
MTA (Model 4, table 2.3). The interaction of WMH and MTA was not significant in the
adjusted model and was not retained (p=0.79).
The ordinal logistic regression model showed that with each one-year increase in
age the odds of more severe GCA increased by 3.5% (Model 5, table 2.3), similar to the
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results obtained in the binary logistic regression model. However, the effect of WMH was
attenuated in the ordinal model, where participants with moderate-to-severe WMH scores
had 6.7 times the odds of more severe GCA compared to participants with no or mild WMH
(Model 5, table 2.3). On the other hand, participants with MTA scores indicating moderateto-severe ratings had 4.1 times the odds of more severe GCA compared to participants with
no or mild MTA (Model 5, table 2.3), which was comparable to the effect observed in the
binary models (Models 2 and 4, table 2.3). The interaction term between WMH and MTA
was not significant in this model and was not retained (p=0.64).
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Table 2.3 Odds ratios (95% CI) for moderate-to-severe global cerebral atrophy (GCA)
based on participant age, white matter hyperintensity (WMH), and medial temporal lobe
atrophy (MTA). Models 1-3 are simple binary logistic regression, and Model 4 is
multivariable binary logistic regression. Model 5 is ordinal logistic regression.
Comparison

Model 1

Model 2

Model 3

Model 4

Model 5

Age (1 year)

1.075

--

--

1.03

1.03

(1.00-1.07)

(1.00-1.06)

3.47

4.05

(1.83-6.60)

(2.48-6.60)

13.60

9.76

6.66

(moderate-to-

(7.60-

(5.17-18.45)

(3.97-

severe vs. no or

24.36)

(1.051.10)
MTA (moderate-

--

5.35

to-severe vs. no

(3.05-

or mild)

9.38)

WMH

--

--

--

11.17)

mild)

GCA = global cerebral atrophy; MTA = medial temporal lobe atrophy; WMH = white
matter hyperintensity burden.

2.4 Discussion:
These data argue that moderate to severe GCA seen on brain imaging studies should
not be solely attributed to normal aging. Instead, CVD, and to a lesser extent AD, should
be considered as the proximate cause of moderate-to-severe GCA in the majority of cases
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(where the prior probability of other causes of atrophy is assumed to be relatively low).
Such understanding may help direct appropriate diagnosis and treatment strategies
for those undergoing evaluation of memory complaints or more significant cognitive
decline that have had structural imaging performed as part of the diagnostic workup.
In the context of potential neuropathologic injury to the brain, age appears to be
only a minor contributor to the development of moderate to severe GCA, in line with the
results from prior studies in the field. Fjell et al. reported that the rate of GCA progression
due to normal aging is 0.5% annually.[133] Similarly, Hua et al. and Scahill et al. also
found a small but significant decrease in regional and whole brain volumes and a
concomitant small increase in ventricular volume with increasing age.[109, 134] The
present findings suggest that more advanced GCA in the moderate to severe range should
not be solely attributed to normal age-related processes, but rather suggest that more
advanced GCA is most likely to be associated with specific disease states such as
subcortical cerebrovascular injuries or neurodegenerative processes, such as AD, that may
be more prevalent with advancing age, but are distinct from the normal aging process.
In AD, based on quantitative studies, the rate of GCA is accelerated compared to
that seen in normal aging (1.25% compared to 0.5% annually), with the fastest rate of
atrophy affecting the medial temporal lobe (2.5% annually).[133] Moreover, the rate of
GCA and ventricular enlargement is accelerated even in young subjects (60-70 years) with
MCI, reflecting the aggressiveness of neurodegenerative disease processes in young
compared to old adults in even the earliest stages of cognitive decline.[134] The pattern of
brain atrophy in AD also differs from that seen in normal aging. In AD, the medial temporal
lobe is involved early in the disease course. Subsequently, the lateral temporal and frontal
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lobes are affected, with eventual involvement of the sensorimotor and visual cortices. Such
progression eventually leads to the development of moderate-to-severe GCA that is not a
part of the normal aging process.[135]
Another important factor to consider as a contributor to the development of
moderate-to-severe GCA is CVD. CVD may be present without evidence for GCA, but if
progressive, can eventually result in moderate to severe GCA secondary to subcortical
vascular damage that can lead to severe white matter atrophy.[136] In addition, progressive
ischemic injury can lead to widespread neuronal atrophy and attrition in the grey matter
that can be visualized on structural imaging as cortical thinning which can further
contribute to the picture of moderate to severe GCA.[137] The STandard for ReportIng
Vascular changes on nEuroimaging working group (STRIVE) has proposed terms and
definitions to describe neuroimaging features of small vessel disease that include using
GCA as an imaging correlate of CVD.[137] Few studies have failed to report an association
between WMH and GCA, and those that have not found such an association have not been
able to control for confounding factors such as small sample sizes or inclusion of
participants with minimal to no CVD risks.[130, 131]
There are several limitations to the present study, including its cross-sectional
design. While we have identified associations between age, MTA, WMH and the presence
or absence of GCA, our data does not assess the temporal sequence of findings, limiting
our ability to draw inferences on potential causality. We have also relied on a convenience
sample drawn from a community-based cohort, enriched in highly educated Caucasian
subjects that may limit the generalizability of the present findings. However, a major
strength of our study also lies in our study sample, which is derived from a well
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characterized community-based cohort, spanning the cognitive continuum from intact
cognition to dementia. Furthermore, the wide age range (41-96 years) increases the
generalizability of the findings at least in regards to lifespan. The use of visual rating scales
derived from standard clinical images is also a major strength, allowing us to examine
structural imaging findings that are part of the normal clinical workup for memory
complaints. These assessments are directly applicable to imaging review procedures used
in routine clinical practice rather than relying on advanced volumetric analysis techniques
that are seldom available to the practicing clinician.
In conclusion, our study demonstrates that qualitative appraisals of structural
imaging findings that are used routinely in clinical settings are an appropriate means of
evaluating the differences between imaging correlates of normal aging and those related to
specific disease processes. Such information may help direct accurate diagnoses and
treatment strategies designed to maximally address cognitive and functional impairments
that may be seen in mild forms as part of the normal aging process, or in more moderate to
severe forms as the sequelae of AD or CVD. Further studies exploring other imaging
features with an eye to practical clinical utility in diagnosis and care are much needed in
the field.
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CHAPTER 3. DISTINCT WHITE MATTER CHANGES ASSOCIATED WITH CSF AMYLOID Β 142 & HYPERTENSION

Summary:
Background: Alzheimer’s disease (AD) pathology and hypertension (HTN) are risk factors
for development of white matter (WM) alterations and might be independently associated
with these alterations in older adults.
Objective: To evaluate the independent and synergistic effects of HTN and AD pathology
on WM alterations.
Methods: Clinical measures of CVD risk were collected from 62 participants in University
of Kentucky Alzheimer’s Disease Center studies who also had CSF sampling and MRI
brain scans. CSF Aβ1-42 levels were measured as a marker of AD, and fluid-attenuated
inversion recovery imaging and diffusion tensor imaging were obtained to assess WM
macro and microstructural properties. Linear regression analyses were used to assess the
relationships among WM alterations, CVD risk and AD pathology. Voxelwise analyses
were performed to examine spatial patterns of WM alteration associated with each
pathology.
Results: HTN and CSF Aβ1-42 levels were each associated with white matter hyperintensities (WMH). Also, CSF Aβ1-42 levels were associated with alterations in normal
appearing white matter fractional anisotropy (NAWM-FA), whereas HTN was marginally
associated with alterations in NAWM-FA. Linear regression analyses demonstrated
significant main effects of HTN and CSF Aβ1-42 on WMH volume, but no significant HTN
× CSF Aβ1-42 interaction. Furthermore, voxelwise analyses showed unique patterns of WM
alteration. associated with hypertension and CSF Aβ1-42.
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Conclusion: Associations of HTN and lower CSF Aβ1-42 with WM alteration were
statistically and spatially distinct, suggesting independent rather than synergistic effects.
Considering such spatial distributions may improve diagnostic accuracy to address each
underlying pathology.
Keywords: Hypertension, Alzheimer’s Disease, Aβ1-42 and white matter alteration.

3.1 Introduction:
Over 50% of individuals who develop dementia have mixed pathologies at
autopsy.[138-140] The two most prevalent contributors to mixed pathology are
Alzheimer’s disease (AD) and cerebrovascular disease (CVD), and intense efforts are
being made to develop in vivo tests for early diagnosis.[138, 140] Antemortem
identification of AD pathology has become easier since the development of in vivo markers
of amyloid and tau using cerebrospinal fluid (CSF) or positron emission tomography (PET)
scans.[41, 141-143] Accurate identification and classification of CVD in vivo, however,
remains challenging. Markers of CVD include areas of hyper-intense signal in white matter
(white matter hyper-intensities, WMH) on T2-weighted MRI of the brain, and more
recently, alterations in microstructural properties of WM such as fractional anisotropy (FA)
detected using diffusion tensor imaging (DTI).[144-146]
WMH also occur in the pre-dementia stage of familial AD, including in those with
no appreciable CVD risks.[17, 18] It remains unclear whether these WM alterations should
be attributed to AD, CVD, or both pathological processes. Further, it is unknown whether
the effects of AD and CVD are independent or synergistic. The present study examined
relationships between CSF beta-amyloid (Aβ1-42) and CVD risk factors with both WMH
volumes and FA values within regions of normal appearing WM. The central analysis of
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the study utilized multiple linear regression to determine whether AD pathology and CVD
risk are independently or synergistically associated with WM alterations. An interaction
term was used to explore potential synergistic effects, while main effects explored potential
independent effects of AD pathology and CVD risk. Voxelwise analyses were then used to
determine the spatial distribution of WMH changes associated with CSF Aβ1-42 levels
and/or CVD risk factors.

3.2

Methods:

3.2.1 Participants:
Participants enrolled in the University of Kentucky Alzheimer’s Disease Center
(UK-ADC) cohort and affiliated clinical trials were included in the present study. All
studies used identical imaging and cerebrospinal fluid collection protocols, and all research
protocols were approved by the University of Kentucky Institutional Review Board. All
participants gave written informed consent.
Inclusion criteria for the current study included a classification of cognitively
normal (CN) or mild cognitive impairment (MCI), which was based on Clinical Dementia
Rating (CDR)[147] global scores: CN (CDR = 0) and MCI (CDR = 0.5). Additionally, all
participants were required to have MRI data that met quality control standards for motion
and artifacts, available CSF Aβ1-42 data, and clinical data regarding current or previous
diagnosis of hypertension (HTN: 1=yes, 0=no), hyperlipidemia (HLD: 1=yes, 0=no), and
diabetes mellitus (DM: 1=yes, 0=no). In addition, data on antihypertensive medication use,
history of cardiovascular disease, atrial fibrillation, cigarette smoking, blood pressure, and
lipid levels were used to calculate a modified Framingham 10-year Stroke Risk Score
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(mFRS) for each participant (FRS was modified because data on left ventricular
hypertrophy were not available).[148]
3.2.2

MRI Protocol and Analysis:
Data were collected on a Siemens 3 Tesla TIM TRIO scanner using a 32-channel

head coil at the University of Kentucky Magnetic Resonance Imaging and Spectroscopy
Center. Two high-resolution 3D T1-weighted images were obtained using a magnetizationprepared rapid acquisition gradient echo (MP-RAGE) sequence [repetition time (TR) =
2530 ms, inversion time (TI) = 1100 ms, echo time (TE) = 2.56 ms, Flip angle = 7 degrees,
1 mm isotropic voxels]. Fluid-attenuated inversion recovery (FLAIR) images were
acquired using a 3D sequence [TR = 6000ms, TI = 2200ms, TE = 338ms, 1mm isotropic
voxels]. DTI used an axial, double-refocused spin-echo, echo planar imaging sequence [TR
= 8000ms, TE = 96ms, FOV = 224mm2, 52 contiguous slices, 2mm isotropic voxels] with
60 non-collinear encoding directions (b = 1000 s/mm2) and 8 images without diffusion
weighting (b0, b = 0 s/mm2).
3.2.2.1 FLAIR Sequence Analysis and WMH Mask Generation:
FLAIR image processing was performed using a previously described
protocol.[149]

Briefly,

MP-RAGE

and

FLAIR

images

were

radiofrequency

inhomogeneity-corrected using the N3-correction algorithm provided in MIPAV
(http://mipav.cit.nih.gov). The two MP-RAGE images were registered to each other using
SPM12 (http://www.fil.ion.ucl.ac.uk/spm/software/spm12) and then averaged. The
averaged MP-RAGE image was then registered to FLAIR image using SPM12. Next, the
FSL (v5.0.9) brain extraction tool[150] was used to remove non-brain tissue from the
average MP-RAGE image to create a binary mask of brain tissue. This mask was then
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applied to the FLAIR image to remove non-brain tissue. Multimodal segmentation was
performed with SPM12 using the average MP-RAGE and FLAIR image. The brain was
segmented into gray matter, two separate white matter segments, CSF, and other tissues
segments using a previously validated segmentation method.[151] The two WM segments
were combined to form a single WM mask, which was dilated and then multiplied with the
FLAIR image to form a FLAIR WM mask. Matlab 2015b was then used to determine the
mean and standard deviation (SD) of the FLAIR WM in each participant by fitting a
Gaussian model curve to the histogram of WM voxels intensity. The FLAIR WM images
were then thresholded at 3 SDs above each participant’s mean value to identify areas of
WMH in that participant. The resulting WMH mask were then manually edited to remove
artifacts around the interventricular septum and inferior slices.[151] The summed volume
of remaining voxels in each participant was used as a measure of WMH volume.
3.2.2.2 DTI Sequence Analysis:
The goal of the DTI analyses was to compute mean FA values within regions of
normal-appearing WM (NAWM) in each participant’s FLAIR image. DTI image
processing was performed using a previously described protocol.[152] Briefly, FSL
(v5.0.9) was used to perform pre-processing for motion and eddy-current correction with
outlier detection and replacement.[153, 154] Following brain extraction, the FMRIB
Diffusion Toolbox (FDT v3.0) was used to fit a voxelwise diffusion tensor model,
determine the eigenvalues, and calculate FA.[155] FA images were registered into FMRIB
FA 1mm space, averaged to form a mean FA image to then generate a common WM
skeleton, and finally project each participants FA image onto the group skeleton using
tract-based spatial statistics (TBSS).[155]
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The same registration parameters were then used to project the FA image to
standard (MNI152 T1 1mm3) space. The common track skeleton was used together with
the WMH images in the TBSS non-FA pipeline.[155] These WMH images were then
subtracted from the TBSS skeleton in order to create a NAWM image for each participant
that comprised only WM outside of WMH. The mean global FA was then extracted from
each participant’s NAWM image using fslstats FSL statistical tool.
3.2.2.3. Cerebral Microbleed Analysis:
Measures of cerebral microbleeds (CMBs) were collected from 62 participants who
had CSF sampling. Gradient recalled echo (GRE) MRI sequence was obtained to assess
CMBs. CMBs were visually rated using Microbleeds Anatomical Rating Scale (MARS).
[156]
3.2.3

CSF Collection and Analysis:
CSF collection and analysis was performed as previously described.[157] In brief,

participants underwent lumbar puncture the same day as MRI scanning. CSF was collected
in the morning after fasting since midnight and stored in a − 80 °C freezer prior to shipment
on dry ice to the Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core
laboratory at the University of Pennsylvania Medical Center. CSF levels of Aβ1-42 were
measured using the multiplex xMAP Luminex Platform (Luminex Corp, Austin, TX) with
Innogenetics (INNO-BIA, AlzBio3; Ghent, Belgium) immunoassay kit as previously
described.[158]
3.2.4

Statistical Analysis:

A. Statistical Analysis:
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Independent samples t-tests and chi-square tests were used to assess differences
between CN and MCI groups in demographic and clinical measures, CSF Aβ1-42, and
measures of WM alteration. Bivariate relationships between CSF Aβ1-42, mFRS, HTN
status, HLD status, DM status, smoking status and quantitative measures of WMH volume
and DTI-based FA measures were investigated using partial correlations controlling for
age and sex.
As HTN was the only CVD risk factors associated with WMH volume, HTN was
used as a marker of CVD risk in further analyses. Next, separate linear regression models
were used to explore the association of HTN and CSF Aβ1-42 with WMH volume and
NAWM-FA. Each model included main effects of HTN and CSF Aβ1-42, a HTN × CSF
Aβ1-42 interaction, and age, sex, and cognitive status as covariates. The interaction term
was included to explore any synergistic effects of HTN and CSF Aβ1-42 on WM alterations.
If the interaction term was not significant, it was removed from the model and the model
was refit to the data in order to explore the independent effects of HTN and CSF Aβ1-42.
Finally, the above models were repeated with the mFRS included as additional covariate.
In order to assess potential contributions from cerebral amyloid angiopathy (CAA),
bivariate relationships of CSF Aβ1-42 with CMBs in the frontal, parietal, temporal, occipital
lobes and the basal ganglia were investigated using partial correlations controlling for age
and sex. Next, linear regression was performed to explore whether WMH and significant
CMBs predicted CSF Aβ1-42 independently after controlling for age, sex, and cognitive
status. SPSS 23 (IBM, Chicago, IL) was used for all statistical analyses, and significance
was set at 0.05.
B. Voxelwise Regression Analysis:
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FSL’s Randomise tool was used to perform exploratory voxelwise regression
analyses to examine the spatial location of WM alteration associated with CSF Aβ1-42 and
HTN. CSF Aβ1-42 (measured in pg/ml) was treated as a continuous variable, whereas the
clinical diagnosis of HTN, systolic BP >139, or diastolic BP > 89 were used as criteria
indicating presence of HTN. Each analysis included either CSF Aβ1-42 or HTN as the
predictor of interest and age, sex, and education as covariates. These models were then
used to identify voxels where the presence of WMH were associated with CSF Aβ1-42 or
HTN. Correction for multiple comparisons across all voxels was performed using the falsediscovery rate (FDR) tool provided with FSL (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FDR),
which uses the distribution of p-values from every voxel in order to determine an
appropriate threshold to reduce false-positives.[159] Results were then compared to the
ICBM-DTI-81 WM labels atlas to identify the tracts that included significant voxels.

3.3 Results:
A total of 62 participants met all criteria for inclusion, including 26 CN (CDR=0)
and 36 MCI (CDR=0.5). Demographic and clinical features of the participants are
presented in Table 3.1 The MCI group had higher percentages of participants with HTN
and HLD than the CN group (p < .001). In addition, CSF Aβ1-42 was significantly lower in
the MCI group than the CN group (p = .005). There was no difference between CN and
MCI groups in other clinical measures or in measures of WM alterations. Results of
bivariate partial correlations controlling for age, sex, and cognitive status are shown in
Table 3.2. The mFRS, HLD and DM were not associated with either WMH volume or FA
in NAWM. HTN and lower CSF Aβ1-42 (which is associated with higher amyloid plaque
burden), however, were both correlated with higher WMH volume (r = 0.30, df = 57, p =
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0.021 and r = - 0.30, df = 57, p = 0.021, respectively). CSF Aβ1-42 but not HTN was
associated with lower FA in NAWM (r = 0.40, df = 57, p = 0.002 and r = -0.23, df = 57, p
= 0.08, respectively).
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Table 3.1 Demographics, clinical, imaging and laboratory characteristics of the study cohort.

Variables
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CN (N=26)

MCI (N=36)

Total (N=62)

Differences CN vs. MCI (p-value)

Age mean ± sd

76.81 ± 6.14

73.47 ± 7.98

74.87 ± 7.40

0.080

Male sex n (%)

9 (34.6)

19 (52.8)

28 (45.2)

0.156

Education mean ± sd

17.08 ± 2.18

16.83 ± 3.67

16.94 ± 3.12

0.764

mFRS mean ± sd

17.58 ± 2.8

16.56 ± 3.1

17 ± 3

0.189

Hypertension n (%)

7 (26.9)

27 (75.0)

34 (54.8)

0.001‡

SBP mean ± sd

135.77 ± 10.77

138.47 ± 16.47

137.34 ± 14.32

0.468

DBP mean ± sd

74.19 ± 9.70

73.89 ± 11.42

74.02 ± 10.65

0.913

Hyperlipidemia n (%)

2 (7.7)

25 (73.5)

27 (43.5)

0.000‡

Diabetes n (%)

4 (15.4)

10 (27.8)

14 (22.6)

0.247

Smoking n (%)

2 (7.7)

1 (2.7)

3 (4.8)

0.567

NAWM-FA mean ± sd

0.59 ± 0.41

0.59 ± 0.55

0.59 ± 0.05

0.987

Aβ1-42 mean ± sd

320 ± 93.14

251.03 ± 90.82

279.95 ± 97.29

0.005¥

WMH volume cc mean ± sd

8.22 ± 9.98

13.30 ± 20.03

11.17 ± 16.65

0.238

CN = cognitively normal; MCI = mild cognitive impairment; mFRS = modified Framingham stroke risk score; SBP = systolic blood
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pressure; DBP = diastolic blood pressure; HLD = hyperlipidemia; NAWM-FA = fractional anisotropy values of the normally appearing
white matter; Aβ1-42 = Cerebrospinal fluid amyloid beta 1-42 levels; WMH = white matter hyperintensities.
‡ Pearson Chi-square

¥ T test (2 sided)

Table 3.2 Partial Correlation of hypertension, CSF amyloid β1-42levels and imaging
measures of micro and macrostructural white matter alteration in study subjects.

HTN

HT

Aβ1-

N

42

--

-0.01

HLD

DM

0.308

mFR

WMH

NAWM

S

volume

-FA

0.207

0.026

0.298*

-0.233

0.188

-

-0.300*

0.400**

*
Aβ1-42

--

--

0.036

0.057
HLD

--

--

--

0.083

0.078

0.056

-0.036

DM

--

--

--

--

-

-0.100

0.019

0.001
mFRS

--

--

--

--

--

-0.041

-0.007

WMH

--

--

--

--

--

--

-0.481‡

volume

Values are partial correlation coefficients adjusted for age, gender and cognitive status;
HTN = hypertension; Aβ1-42 = Cerebrospinal fluid amyloid beta 1-42 levels; HLD =
hyperlipidemia; DM = diabetes mellitus; mFRS = modified Framingham stroke risk score;
WMH = white matter hyperintensity; NAWM-FA = fractional anisotropy values of the
normally appearing white matter.
* P ≤ 0.05, ** P ≤ 0.01, ‡ P ≤ 0.001
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Results of linear regression analysis examining the effects of CSF Aβ1-42, HTN, the
CSF Aβ1-42 × HTN interaction on WMH volume, controlling for age, sex, and cognitive
status are shown in Table 3.3 (Model 1). Results after removing the non-significant
interaction term are also shown (Model 2). Models 1 and 2 were repeated with the inclusion
of mFRS as an additional covariate (Table 3.3; Models 3 and 4, respectively). Results of
linear regression analysis examining the effects of CSF Aβ1-42, HTN, the CSF Aβ1-42 ×
HTN interaction on NAWM-FA controlling for age, sex, and cognitive status are shown in
Table 3.4 (Model 1). Results after removing the non-significant interaction term are also
shown (Model 2). Models 1 and 2 were repeated with the inclusion of mFRS as an
additional covariate (Table 3.4; Models 3 and 4, respectively).
Results from the voxelwise regression analyses demonstrated both HTN and CSF
Aβ1-42 were primarily associated with WMH in different areas, with 95% of HTN-related
WMH voxels and 90% of CSF Aβ1-42 -related WMH voxels being unique (i.e., nonoverlapping) (Figure 3.1). WMH associated with HTN were primarily located in the right
inferior fronto-occipital fasciculus, right superior longitudinal fasciculus, and bilateral
periventricular WM along the body of the lateral ventricles. In contrast, WMH associated
with CSF Aβ1-42 were primarily located at the posterior corona radiata bilaterally and
periventricular regions near the anterior horns of the lateral ventricles. The primary area of
overlap was in the posterior portion of the right cingulum (Figure 3.1).
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Table 3.3 Linear regression models to examine the effects of hypertension and
Cerebrospinal fluid amyloid beta 1-42 levels on white matter hyperintensity burden.
Aβ1-42

HTN

Aβ1-42 ×
HTN

Model 1a (F5,56 = 7.7, R2 = 0.409, p <

Β = -0.28

Β = 0.30

Β = 0.03

0.001)

(.026)

(.017)

(.829)

Model 2a (F6,55 = 6.3, R2 = 0.408, p <

Β = -0.28

Β = 0.30

--

0.001)

(.016)

(.016)

Model 3b (F7,54 = 5.8, R2 = 0.432, p <

Β = -0.28

Β = 0.32

Β = 0.04

0.001)

(.024)

(.012)

(.728)

Model 4b (F6,55 = 6.9, R2 = 0.431, p <

Β = -0.29

Β = 0.32

--

0.001)

(.013)

(.011)

Linear regression models using white matter hyperintensity (WMH) volume as the
dependent variable. Values shown are standardized β-coefficients with p-values in
parentheses. Predictors of interest were CSF levels of Aβ1-42, HTN, and Aβ1-42 × HTN
interaction (Models 1, 3). The analyses were repeated without the non-significant
interaction term (Models 2, 4). aCovariates included in models 1 & 2 were age, sex, and
cognitive status. bCovariates included in models 3 & 4 were age, sex, cognitive status, and
mFRS.

53

Table 3.4 Linear regression models to examine the effects of hypertension and
Cerebrospinal fluid amyloid beta 1-42 levels on white matter microstructural alterations.
Aβ1-42

HTN

Aβ1-42 × HTN

Model 1a (F6,55 = 7.0, R2 = 0.432, p <

Β = 0.016

Β = -0.01

Β = -0.01

0.001)

(.007)

(.065)

(.143)

Model 2a (F5,56 = 7.8, R2 = 0.409, p <

Β = 0.018

Β = -0.011

--

0.001)

(.001)

(.067)

Model 3b (F7,54 = 5.9, R2 = 0.434, p <

Β = 0.016

Β = -.0011

Β = -0.008

(.007)

(.063)

(.138)

Β = 0.018

Β = -0.011

--

(.001)

(.067)

0.001)
Model 4b (F6,55 = 6.4, R2 = 0.410, p <
0.001)

Linear regression models using the fractional anisotropy values of the normally appearing
white matter (NAWM-FA) as the dependent variable. Values shown are standardized βcoefficients with p-values in parentheses. Predictors of interest were CSF levels of Aβ1-42,
HTN, and Aβ1-42 × HTN interaction (Models 1, 3). The analyses were repeated without the
non-significant interaction term (Models 2, 4). aCovariates included in models 1 & 2 were
age, gender, and cognitive status. bCovariates included in models 3 & 4 were age, gender,
cognitive status, and mFRS.
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Figure 3.1 Distinct spatial distribution of white matter hyperintensities related to
hypertension and CSF amyloid β1-42 levels.

The spatial distribution of white matter hyperintensities (WMH) related to hypertension
(HTN) (red) and Cerebrospinal fluid amyloid beta 1-42 levels (Aβ1-42) (green) shows
primarily distinct distributions with minimal overlapping areas (blue). WMH associated
with HTN occur primarily in deep cortical white matter and along the body of the lateral
ventricles. WMH associated with Aβ1-42 occur primarily near the ventricular horns and the
posterior corona radiata. Areas of WMH are displayed on the FMRIB58 FA 1mm3 brain.
Contiguous 1mm slices are shown starting from MNI z = 0 at the top left and MNI z = 48
at the bottom right. All images are shown in radiological orientation (anatomical right is
on the left side of the image).
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In order to assess the impact of CMBs on the relationships observed between CSF
Aβ1-42 and WM alterations, partial correlations were performed to examine the
relationships of Aβ1-42 with basal ganglia and lobar CMBs (in frontal, parietal, temporal,
and occipital lobes separately). Results of the analyses demonstrated that Aβ1-42 was
associated with parietal CMBs (r = -0.28, p = .037) but not with any other CMBs (p >
0.05). A linear regression analysis was then performed to examine whether parietal CMBs
and WMH independently predicted CSF Aβ1-42. Results demonstrated that Aβ1-42 was
significantly predicted by WMH volume (β = -0.32, p =.025) and only marginally predicted
by parietal CMBs (β = -0.25, p = .06) while controlling for age, sex, and cognitive status.

3.4 Discussion:
Results from this study demonstrate that CSF levels of Aβ1-42 and HTN are each
associated with WM damage, manifesting as both overt areas of WMH and microstructural
alterations in NAWM. Importantly, these processes appear to independently contribute to
WM changes and affect spatially distinct areas of WM. These data demonstrate that
pathologies underlying or caused by CSF Aβ1-42 and HTN exert additive rather than
synergistic effects on WM alteration. Our work also raises the question of whether the
nature of white matter alteration associated with HTN is the same as that associated with
CSF Aβ1-42. Since the spatial distributions of WM changes were distinguishable (HTN vs
CSF Aβ1-42), equivalent underlying mechanisms should not be assumed, despite some
similarities in their appearances on MRI. Assuming that both types of WM alteration are
deleterious, it follows that treatment of mixed disease states may require interventions
aimed at both processes to achieve maximal clinical efficacy.
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Initial analyses sought to determine whether CVD risk factors and/or CSF Aβ1-42
levels were associated with WM alteration as assessed by overt WMH or subtler
microstructural changes within NAWM that are not detectable at the macrostructural level.
The modified Framingham CVD risk score was not associated with either marker of WM
alteration. Previous studies examining the relationship between the mFRS and WM
alterations have been equivocal with one study finding a relationship[160] and another
failing to find such a relationship in older adults.[161] These discordant findings may be
due to differences in the cohorts, including clinical, environmental, and cultural
characteristics. In addition, the Framingham CVD risk score is intended to predict future
CVD, which may account for the lack of cross-sectional relationship between mFRS and
WM alterations. Of note, a recent study failed to find a relationship between mFRS and
WM but did find that mFRS predicted future cognitive decline.[161]
HTN was associated with both WMH volume and FA in NAWM, which is
consistent with previous reports.[162, 163] The potential mechanisms underlying the
association between HTN and WM alteration are unclear, but several explanations have
been proposed. It is possible that that reduced cerebral blood flow could contribute to
transient ischemic injury or that HTN-induced endothelial damage could result in
extravasation of blood products into WM tissue resulting in injury.[37, 164, 165] WMH
may represent areas of reduced vascular integrity,[166] whereas alteration in NAWM may
include decreased myelin organization, lower axonal coherence, or decrease in axonal
numbers otherwise related to reduced vascular integrity.[167]
Lower CSF Aβ1-42 levels were also associated with both higher WMH volume and
lower FA in NAWM. These findings are consistent with previous studies, which found that
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WMH volume is higher[17, 18] and FA is lower[168, 169] in AD brain compared to
healthy controls. The exact mechanism underlying these relationships also remains unclear,
but several possibilities exist. First, we noted that soluble Aβ1-42 oligomers were present in
WM and were associated with loss of axons as well as breakdown in myelin content.[170,
171] Further, soluble Aβ1-42 is toxic to oligodendrocytes and inhibits formation of new
myelin sheaths in vitro.[172, 173] It is also possible that Aβ1-42 may indirectly influence
WM through increased inflammation,[174] decreased cerebral blood flow secondary to a
hypocholinergic state,[175] or damage to blood vessels secondary to cerebral amyloid
angiopathy.[18, 176]
The most important finding of the present study is that a history of HTN and CSF
Aβ1-42 levels are independently associated with WM alterations and have additive effects.
Of note, AD and HTN often coexist in older adults.[177] However, linear regression
analyses demonstrated that there was no significant interaction between CSF Aβ1-42 levels
and HTN on WM changes. Further, the main effect of CSF Aβ1-42 and HTN were both
significant when assessed simultaneously, indicating that these measures constitute
independent predictors of WM changes. Several studies suggest that Aβ amyloidosis and
HTN are independent predictors of cognitive outcomes,[178, 179] but this is the first
evidence that CSF Aβ1-42 levels and HTN are independently associated with WM
alterations in older adults. These findings suggest that WM alterations could be viewed as
the sum of effects from both AD and CVD pathology, rather than thought of as either AD
or CVD modifying the effect of the other on WMH burden. This has important implications
for therapeutic interventions, since treating one pathology will only address WM alteration
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from that disease mechanism but may have no significant impact on WM changes related
to the other condition.
After identifying statistically independent relationships of CSF Aβ1-42 levels and
HTN with WM alteration, we sought to determine if this independence was due to spatially
distinct patterns of WM alteration associated with each pathology. We found minimal
overlap between areas of WM alterations associated with CSF Aβ1-42 and HTN; 95% of
HTN-associated WMH and 90% of Aβ-associated WMH were unique. Consistent with
previous studies in familial AD, CSF Aβ1-42 was primarily associated with WM alteration
in posterior regions.[17, 18, 176] Although much of the evidence for the relationship
between Aβ1-42 and posterior WM alteration comes from studies of dominantly-inherited
AD, the present study provides support for a similar relationship in sporadic late-onset AD.
In contrast to Aβ1-42-associated WM alterations, HTN-associated WM change was
primarily observed in deep WM. Many of these areas are near watershed regions between
the middle cerebral artery and posterior cerebral artery distributions. These findings are
consistent with previous studies that found CVD risk is associated with greater WM
alteration in the watershed regions and deep WM.[164, 165]
An important possibility that must be considered is that the association between the
Aβ1-42 and WM alterations in these posterior regions is mediated by cerebral amyloid
angiopathy (CAA), which has a predilection for parietal-occipital cortex. [180] In our
study, we found a relationship between CSF Aβ1-42 and CMBs in the parietal lobe, which
is consistent with extensive previous work. [181, 182] However, regression analyses
demonstrated that these amyloid-associated CMBs did not account for the significant
relationship between amyloid and WMHs. These results suggest that CAA is likely one of
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multiple mechanisms that contribute to WM alterations associated with increasing amyloid
in the brain.
There are several limitations to the present study. The cross-sectional design
allowed for measurement of correlations among HTN, CSF Aβ1-42 levels and WMH/FA in
NAWM, but we did not assess the temporal sequence of these changes, precluding causal
inferences. In addition, the sample size may have led to insufficient power to detect small
effects. Further, cardiovascular risk measures were assessed using dichotomous variables
(either present or absent) and did not account for medication control or adherence, disease
duration, and/or severity. This may mask potential relationships that exist between these
cardiovascular risk measures and WM alterations. Additionally, our sample included only
those without dementia. It is unclear whether these relationships are present in individuals
with severe disease(s).

Also, the present study did not examine relationships with

cognition. Despite independent effects on WM, CVD risk and AD pathology may have a
different relationship with cognition as demonstrated by a recent study reporting
synergistic effects of CVD risk and AD pathology on cognitive decline. [26] Finally,
amyloid PET scans were not collected as part of this study. Previous work has
demonstrated spatial overlap between CAA and PET amyloid binding. [183, 184]
Therefore, future studies should seek to include PET imaging to examine whether these
areas of WM alteration found in the present study share overlap with these same regions
of increased amyloid-PET binding in CAA.
In conclusion, the present study demonstrates that the effects of HTN and CSF Aβ142

levels on WM alteration may be additive rather than synergistic, with each associated

with distinct spatial distributions of WM alteration. Considering such spatial distributions
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may improve diagnostic accuracy and optimal development of treatment paradigms that
address CVD and AD, either separately or in combination. It is unclear whether the
underlying pathophysiology and injurious mechanisms of these alterations are the same in
the different brain regions. Further studies are needed to explore whether these distinct
spatial patterns of WM alteration are associated with different cognitive processes and/or
clinical outcomes.
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CHAPTER 4. WHITE MATTER HYPERINTENSITY REGRESSION IS ASSOCIATED WITH
DECREASED BRAIN ATROPHY AND IMPROVEMENT IN MEMORY PERFORMANCE
Summary:
Background: Subcortical white matter hyperintensities (WMH) in the aging population
frequently represent vascular injury that may lead to the cognitive sequelae. The dynamic
nature of WMH have been well described in the literature, although the factors underlying
WMH regression remain poorly understood.
Methods: A sample of 377 participants from the Alzheimer’s Disease Neuroimaging
Initiative 2 (ADNI2) were included in the analysis. Inclusion criteria required available
data regarding WMH volumetric quantification, structural brain measures (i.e., brain
volume), cognitive composite measures (memory and executive function), CSF tau and
Aβ, and Amyloid PET data at baseline and after approximately 2 years, allowing changes
in these measures (Δ) to be calculated. Subjects were categorized into three groups based
on WMH change over time, including those that demonstrated regression (n=96; 25.5%),
stability (n=72; 19.1%), and progression (n=209; 55.4%).
Results: There were no significant differences in age, education, sex, or cognitive status
between the regression, stable, and progression groups. Analysis of variance demonstrated
significant differences in changes in brain volume between the progression and regression
(p = 0.004) and the progression and stable groups (p = 0.012). Memory assessments
improved over time in the regression and stable groups compared to those in the
progression group in whom these measures declined (p = 0.003; p = 0.018). Finally,
within-groups, it was determined that Δ WMH was positively correlated with tau/Aβ in the
progression, but not regression group (p = 0.036; p = 0.219).
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Conclusions: WMH regression is associated with decreased brain atrophy and
improvement in memory performance over two years compared to those with WMH
progression. These data suggest that WMH are dynamic and directly reflect both declines
and improvements in cognitive performance depending on volumetric change over time.
In addition, while we currently lack therapeutic interventions to halt or reverse AD, the
dynamic WMH change evident in our data clearly suggests that the ability to reverse cSVD
exists today. Further work elucidating the factors associated with WMH regression,
stability, and or progression may help identify targets for therapeutic intervention for cSVD
related cognitive decline and dementia in the aging population.

4.1 Introduction:
Cerebral white matter hyperintensities (WMH) are non-specific, subcortical, high
intensity signals found on T2 magnetic resonance imaging (MRI). Late-life WMH are
thought to largely represent cerebrovascular injury resulting from cerebral small vessel
disease (cSVD).[16] Such injury may lead to neuronal circuit dysfunction in affected areas
that can be associated with vascular cognitive impairment and dementia. A number of
previous studies have demonstrated an association between longitudinal progression of
WMH lesion volume and worsening cognitive impairment.[185-188] In contrast, the
cognitive sequelae of WMH volume regression has not been studied systematically,
although several studies have reported cases of WMH regression without examining the
relationship of such findings with cognitive outcomes. The authors of these previous
reports have described the phenomena of WMH regression as both poorly understood and
in need of further study.[189, 190]
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It is possible that WMH regression may simply reflect imaging or methodological
confounders as opposed to representing a true biological phenomenon.[191] The use of
standardized imaging sequences, scanners, and head coils across longitudinal visits, along
with regular scanner calibration and identical processing techniques with uniform intensity
corrections, such as that used in the ADNI study, are required to overcome imaging and
methodological confounders that may be related to WMH regression. ADNI was launched
in 2003 as a public/private partnership designed to assess biological and clinical markers
to assess AD progression, and up to date information can be found at www.afni-info.org.
As a biological phenomenon, it is possible that regression of WMH volume
represents simple gliotic contraction and/or resultant microvascular encephalomalacia
resulting from static ischemic injury. If WMH regression represents such a biological
phenomenon, it should be associated with greater global brain atrophy and stable, or
possibly improved, cognitive function as seen in many individuals post-stroke.
Alternatively, WMH regression could potentially reflect a longitudinal reduction in
inflammatory changes and focal edema associated with cSVD, and if so, such changes
should be associated with improved cognition despite greater apparent brain atrophy
associated with resolution of focal edema. Lastly, it remains possible that WMH regression
represents a potentially healing or regenerative process, that would be associated with
reduced brain atrophy and improvement in cognitive performance. A theoretical
framework to assist with interpreting such longitudinal changes is provided in Table 4.1.
The present study explored these potential hypotheses responsible for WMH regression by
examining the differences in cognitive and structural brain changes (i.e. brain atrophy) that
occur in the setting of WMH volume regression through the analysis of existing
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Table 4.1 Possible etiologies for cerebrovascular-related white matter hyperintensities that
regress over time and the expected associations with cerebral atrophy and cognitive
performance.

Possible

Potential cause

Expected

Expected association

etiology for

of regression

association with

with cognitive

cerebral atrophy

performance

Increased atrophy

No change in cognitive

WMH
Irreversible

Gliotic

ischemic injury

contraction and

performance

microscopic
encephalomalacia
Inflammation

Resolution of

Increased atrophy

Improvement in

associated with

inflammation and

secondary to reduced

cognitive performance

irreversible

edema with

inflammatory edema

ischemic injury

restoration of
normal function
in the penumbra

Reversible

Healing process

Decreased atrophy

ischemic injury

Improvement in
cognitive performance

longitudinal data collected as part of the Alzheimer’s Disease Neuroimaging Initiative 2
(ADNI 2). Also, given that previous work has demonstrated that both AD and cSVD
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contribute to WMH. We hypothesize that WMH progression would more likely be
associated with greater AD pathology.

4.2

Methods:

4.2.1 Participants:
The study cohort was comprised of 377 ADNI 2 participants who had WMH
quantification both at baseline and at 2-years +/- 3 months (UC Davis; DeCarli et al., 2013).
Inclusion criteria required complete demographic information, diagnostic information
within 1-year of the T2 fluid-attenuated inversion recovery (FLAIR) scan used for WMH
quantification at baseline, a T1-weighted (MPRAGE) image and FreeSurfer structural
segmentation[192, 193] within 1-year of the baseline FLAIR images, as well as appropriate
neurocognitive metrics for assessments of memory,[194] executive function (EF)[195] and
atrophy composite scores within 1-year of the baseline FLAIR images. The memory
composite included the Rey Auditory Verbal Learning Test (RAVLT), the cognitive
component of the Alzheimer’s Disease Assessment Scale (ADAS-Cog), the Folstein MiniMental State Examination (MMSE), and Wechsler Logical Memory Scale scores, while
the executive function composite included the Clock Drawing test, Trail Making test,
Category Fluency (animal and vegetable), Wechsler Adult Intelligence Scale-Revised
(WAIS-R) Digit Span and Digit Symbol tests. Participants who did not have FreeSurfer
structural information or neurocognitive composite scores at follow-up were excluded from
the analyses. No other subjects were excluded. Details of ADNI clinical and methodology
have been published.[196, 197]
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4.2.2

MRI acquisition
Due to the multi-center design of the ADNI study, the exact scanner manufacturer

and model, and scanner-specific imaging protocol varied between, but not within,
participants. Across participants, all FLAIR images were 2-dimensionally acquired in the
axial plane with 0.9 by 0.9-millimeter voxels and 5 millimeter thickness. All scans were
approximately 4-minutes in duration. Scans contained 36-42 slices with minimum matrix
size of 220 by 220 millimeters (256 by 237 maximum), and a 9-11 second TR. Scanning
parameters were identical within participants between the two-time points. As a result, the
reported WMH progression, stability, and regression measures fulfill the criteria needed to
control for radiological and methodological confounders.[191] Further information on the
ADNI2 scanner protocol can be accessed on the ADNI website at www.afni-info.org.
White Matter Hyperintensity Calculations
WMH volumes were calculated using the 4-tissue segmentation method.[198]
Briefly, FLAIR images were co-registered to the T1 image, inhomogeneity-corrected and
non-linearly aligned to a minimal deformation template (MDT) using the T1
transformation and the FSL toolbox.[199, 200] WMHs were estimated in MDT space using
Bayesian probability and prior probability maps. Binary WMH masks were created using
a threshold of 3.5 SD above the mean. Volume from WMH were then calculated after backtransformation into native space. Gray, white, and CSF measurement are segmented using
an expectation-maximization algorithm. WMH were ultimately subtracted from normal
white matter volume and reported in cubic centimeters.
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Longitudinal Change Calculations
Changes in the various measures (Δ) were calculated by subtracting the baseline
value from the value at the 2-year follow-up. Positive values indicate increases whereas
negative values indicate decreases between the two time points. For WMH volume change,
a negative value indicates regression (i.e., less WMH volume at follow-up) whereas a
positive value indicates progression (i.e., more WMH volume at follow-up).
WMH Categorization
WMH net volume change between the baseline and the follow up visit was used to
calculate Δ WMH.

Participants were initially grouped based on Δ WMH volume

(Regression, Stable, and Progression) using a percentile-based approach in which the
percentile for no change was first identified (the 35th percentile). Although definitions
based on standard deviations were initially considered, the notable leptokurtic distribution
(Figure 4.1) of the data pre-empted such classification as only the most extreme values
would be defined outside of the Stable group. Ultimately, we defined Stable the stable
group as representing the 25th- 45th percentile of the study participant distribution. This
corresponded to +/- Δ of 150 mm3 of WMH lesion volume. Subjects classified in the
regression group showed reductions in WMH volume greater than 150 mm3 and those
classified in the progression group showed increase in WMH volume greater than 150
mm3.
Atrophy Composite Calculation
In addition, we sought to measure changes in brain and ventricular volume to
estimate changes in global brain atrophy that may be related to WMH changes. Gray and
white matter segmentation[198] from the four-tissue ADNI classification were combined
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Figure 4.1 White matter hyperintensity distribution in the sample studied.
A) The true distribution of the data, showing notable leptokurtosis. Black arrows indicate
standard deviation, demonstrating why standard deviation was not deemed an appropriate
criterion for separating groups. B) Divisions of the three WMH groups. Visualization only.

to produce a total brain volume (cm3), but this measure alone does not specifically account
for the volumetric changes in the ventricles, which is associated with both WMH
changes[201] and AD-related neurodegenerative processes.[202] Therefore, the volume of
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the lateral ventricles (cm3) were estimated using FreeSurfer. Although these measures
were examined individually (Tables 1, 2, and 3), the final measure was a composite that
used the z-scores of brain volume subtracted from the z-scores from the lateral ventricles
(higher value means less brain volume and larger ventricles), which accounts for both
periventricular and subcortical atrophy (ventricular volume) as well as more cortical-based
whole brain atrophy (brain volume).
Cerebrospinal Fluid Amyloid beta and Amyloid PET Difference Among WMH Growth
Category:
We further explore the differences in the cerebrospinal fluid (CSF) Amyloid beta
(Aβ) and tau among the three WMH growth categories. In addition, we looked at the whole
brain and regional Aβ deposition relationship with the WMH progression and regression.
4.2.3

Statistical Analysis:
ANOVAs were used to compare age, education, Δ WMH, Δ Memory, Δ EF, and Δ

Brain Composite in WMH progression, regression, and stable groups. Chi Square was
used to compare sex, marital status, cognitively normal, MCI, and AD differences. Withingroups, partial-correlation coefficients controlling for age and sex were used to examine
WMH volume (as a continuous variable), Δ brain volume composite, Δ memory, and Δ
EF. Between-group differences in Δ brain volume composite, Δ memory, and Δ EF
between the 3 groups was examined using ANCOVA with both age and sex as covariates.
In this exploratory study, we did not include correction for multiple comparisons, and so
the value for statistical significance was set as an uncorrected two-tailed p< 0.05.
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4.3 Results:
Participants were 72 ± 7.2 years old, 48.3% female, had 16.5 ± 2.6 of education
with 55.7% having MCI, 37.4% being cognitively normal, and 6.9% having AD (Table
4.2). There were no significant differences between regression, stable, and progression
groups in age, education, sex, marital status, diagnosis, or Δ EF.
25.5% of the participants were classified in the WMH regression group, 19.1%
were classified as stable. and 55.4% were classified in the WMH progression group.
ANCOVA revealed that there were differences in Δ atrophy composite between
progression and regression (p = 0.004) and progression and stable groups (p = 0.012, Table
3). Longitudinally, memory improved in the regression and stable groups compared to
progression (p = 0.003; p = 0.018 respectively, Table 4.3). There were no differences
between any groups in Δ EF (p = 0.306, Table 4.3).
For all participants, Δ WMH was negatively correlated with Δ atrophy composite
(r = - 0.175, p< 0.001), Δ EF (r = -0.121, p < 0.021), and Δ memory (r = -0.165, p = 0.002).
Within-group analyses revealed that Δ WMH was not correlated with Δ atrophy composite
or Δ memory in the WMH regression group (Table 4.4). There was a statistically
significant negative correlation in the WMH regression group with Δ EF (p = 0.041),
indicating that increased WMH regression (more negative value) was associated with
increased EF performance. Δ WMH was not correlated with Δ EF in the WMH progression
group but was positively associated with both the Δ atrophy composite (p = 0.025) and
negatively associated with Δ memory (p = 0.049). There was no association between Δ
WMH and Δ atrophy composite, Δ memory, or Δ EF in the stable group (Table 4.4).
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Finally, within-groups, it was determined that Δ WMH was positively correlated
with tau/Aβ in the progression, but not regression group (Table 4.5; p = 0.036; p = 0.219).
The amyloid PET scans showed that Δ WMH was not positively correlated with the whole
brain amyloid concentrations (p = 0.097), but was in the temporal region (p = 0.049) in the
progression group. There were no significant differences found in the regression group
(Table 4.5).
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Table 4.2 Demographic, clinical, imaging, and change scores for subjects demonstrating progression, stability, and regression in white
matter hyperintensity volumes.
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Criteria

Progressors (n=209)

Regressors (n=96)

Stable (n=72)

Significance

N (P, R, S)

Age (mean, SD)

72.6 (7.1)

72.1 (7.2)

70.3 (7.2)

0.063 #

209, 96, 72

Education (mean, SD)

16.4 (2.6)

16.6 (2.5)

16.7 (2.4)

0.661 #

209, 96, 72

Female (n, %)

106 (50.7)

41 (42.7)

35 (48.6)

0.429 ^

209, 96, 72

Currently Married (n, %)

157 (75.1)

74 (77.1)

54 (75.0)

0.926 ^

209, 96, 72

Cognitively Normal (n, %)

71 (34.0)

38 (40.0)

32 (44.4)

0.250 ^

209, 96, 72

MCI (n, %)

119 (56.9)

55 (57.3)

36 (50.0)

0.555 ^

209, 96, 72

AD (n, %)

19 (9.1)

3 (3.1)

4 (5.6)

0.143 ^

209, 96, 72

Baseline WMH (mean, SD)

7.177 (10.3)

8.025 (10.5)

1.932 (1.9)

<0.001#*

209, 96, 72

Follow Up WMH (mean, SD)

9.145 (11.6)

6.737 (9.4)

1.944 (1.9)

<0.001#*

209, 96, 72

ΔWMH (mean, SD)

1.97 (2.5)

-1.29 (1.8)

0.012 (0.079)

<0.001 #*

209, 96, 72

Δ Memory (mean, SD)

-0.112 (0.38)

0.023 (0.36)

0.018 (0.35)

0.003 #*

203, 93, 69

Δ EF (mean, SD)

-0.094 (0.65)

0.011 (0.65)

-0.003 (0.58)

0.335 #

202, 94, 69

Δ Atrophy Comp (mean, SD)

0.273 (1.6)

-0.293 (1.68)

-0.335 (1.34)

0.002 #*

202, 95, 67

Δ Brain Volume (mean, SD)

-6.071 (21.1)

-0.511 (22.1)

-2.181 (19.5)

0.076 #

209, 96, 72

Δ Ventricular Vol (mean, SD)

4.160 (3.961)

3.033 (3.745)

2.619 (2.681)

0.003 #*

202, 95, 67

# indicates the p-value from ANOVA (uncorrected); ^ indicates the p-value from Pearson’s Chi Square test; * indicates statistically
significant
Abbreviations: SD, standard deviation; MCI, mild cognitive impairment; AD, Alzheimer’s disease; WMH, white matter
hyperintensities; EF, executive function composite.
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Table 4.3 ANCOVA results examining brain volume composite, memory change, and EF change in all three groups. Age and gender
were used as covariates.
ANCOVA
Dependent Variable

Post-hoc Comparisons

Δ Atrophy Composite

n

Mean Difference

364

p-value
0.004*

75

Progression/Regression

196/94

0.564

0.004*

Progression/Stable

196/66

0.564

0.012*

Regression/Stable

94/66

0.000

0.999

Δ Brain Volume

377

0.069

Progression/Regression

209/96

5.684

0.030*

Progression/Stable

209/72

4.010

0.169

Regression/Stable

96/72

1.678

0.612

Δ Ventricular Volume

364
Progression/Regression

202/95

0.008*
1095

0.017*

Progression/Stable

202/67

1369

0.009*

Regression/Stable

95/67

274

0.640

Δ Memory

365

0.004*

Progression/Regression

203/93

0.136

0.003*

Progression/Stable

203/69

0.123

0.018*

Regression/Stable

93/69

0.014

0.815

Δ EF

365

0.306

76

Progression/Regression

202/94

0.113

0.155

Progression/Stable

202/69

0.087

0.330

Regression/Stable

94/69

0.026

0.795

* indicates significant at p < 0.05.
Abbreviations: WMH, white matter hyperintensities; EF, executive function composite.

Table 4.4 Partial correlation between WMH change and brain volume composite, memory
change, and EF change in regression, progression, and stable groups separately. The
variables controlled for are age and gender.
Partial
Correlations
Regression

Δ WMH

N=96

Δ Atrophy

Δ Brain

Δ

Δ

Volume

Ventricular

Memory

Δ EF

r

0.121

-0.001

0.202

0.033

-0.213

P

0.248

0.991

0.052 &

0.759

0.041 *

n

95

96

95

93

94

Progression

N=209

Δ WMH

r

0.158

-0.125

0.122

-0.139

-0.049

P

0.025 *

0.072 &

0.085 &

0.049 *

0.491

n

202

209

202

202

201

Stable

N=72

Δ WMH

r

0.131

-0.073

0.111

-0.063

-0.044

P

0.298

0.549

0.380

0.610

0.726

n

67

72

67

69

69

* indicates significant at p < 0.05; & indicates marginally significant/trend.
Abbreviations: WMH, white matter hyperintensities; EF, executive function composite.
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Table 4.5 Partial correlation between WMH change and Tau/Aβ, Amyloid Total (whole
brain), and regional analysis in regression, progression, and stable groups separately.

Partial
Correlations
Tau/Aβ

Regression

Amyloid

Frontal

Cingulate

Parietal

Temporal

Total
Delta WMH

r

0.136

-0.046

-0.53

-0.040

-0.059

-0.027

p

0.219

0.660

0.611

0.701

0.572

0.729

n

85

96

96

96

96

96

r

0.151

0.116

0.126

0.096

0.096

0.137

p

0.036*

0.097

0.070^

0.171

0.167

0.049*

n

197

209

209

209

209

209

r

-0.041

0.074

0.098

0.111

0.061

0.011

p

0.750

0.542

0.418

0.359

0.616

0.926

n

64

72

72

72

72

72

Progression
Delta WMH

Stable
Delta WMH

The variables controlled for are age and sex. * indicates significant at p < 0.05, ^ indicates
statistical trend.
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4.4 Discussion:
Our results demonstrate that WMH regression is associated with decreased brain
atrophy and improvement in memory performance over a period of 2-years compared to
participants with progressive WMH changes (Table 4.3). Additionally, participants with
progressive WMH changes had increased atrophy and poorer memory performance as a
function of Δ WMH (Table 4.4). Consistent with prior reports, our data also show that
WMH progression is associated with worsening memory[203-205] and that larger WMH
volumes are associated with greater brain atrophy.[126]
Furthermore, our data showed that participants with progressive WMH changes had
a strong correlation with Tau/Aβ and the amyloid deposition in the temporal lobe detected
by the Amyloid PET scan.[17]
WMH progression and regression have been reported in smaller cohorts,[189, 190,
202, 206] and a stable group has also been identified in other studies.[190, 202] Several
studies have reported that WMH progression is associated with greater cognitive
decline,[187, 188] however, previous studies have not reported on the potential
associations between WMH regression and changes in global atrophy or cognitive test
performance over time.
We used the conventional net change in the WMH between the baseline and the
follow up visits together with the percentile approach to categorize the dynamic changes
into three groups (progression, stable and regression). We found that about 25.5% of study
participants showed WMH regression, which is similar to the 21.5% reported by
others.[207] In addition, 19.1% of the cohort remained stable and 55.4% showed WMH
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progression over 2-years. These data add to the existing literature suggesting that WMH
volume is a dynamic feature of aging and age-related neurologic disease.
There are several possible explanations for the observed WMH regression seen in
this and other studies.

WMH regression could be due to imaging acquisition or

methodological confounders such as the use of different scanners across visits, lack of
scanner calibration, lack of standardized acquisition parameters, differences in postacquisition processing techniques such as registration or segmentation pipelines, which
may all affect the accuracy of the WMH volume change calculation.[191] Use of the ADNI
cohort and WMH volumes from the validated UCD 4-tissue segmentation method for this
study minimized such effects, suggesting instead that the observed dynamic nature of
longitudinal WMH volumes reflects meaningful biological change.
Biological causes for WMH regression could include gliotic scarring and
microstructural encephalomalacia due to irreversible ischemic parenchymal injury,
resolution of secondary inflammatory processes as a result of irreversible ischemic
damage, or could instead reflect resolution or healing of reversible ischemic injury. The
associations of WMH regression with measures of global cerebral atrophy and cognitive
change over time would be expected to differ between these possibilities as highlighted in
Table 4.1.
If WMH regression were the result of gliotic scarring and microstructural
encephalomalacia, it would be expected that such change would be associated with
increased cerebral atrophy and stable cognition. In such a scenario, acute small subcortical
strokes and lacunar infarcts, which mimic WMH, could account for WMH regression
through the natural course of temporal evolution. Such permanent lesions eventually
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reduce in diameter over time, which could in part account for the observed WMH
regression seen in this and other studies.[202, 208] The current data, however, argue
against this possibility as retraction and temporal evolution of ischemic lesions would be
expected to result in increased Δ brain volume which is contrary to the present findings in
which WMH regression was associated with decreased Δ brain volume .
It is also possible that WMH regression may be due to resolution of inflammatory
processes and focal edema related to irreversible ischemic injury. This hypothesis is
supported by prior work demonstrating that parenchymal edema develops early during the
WM vascular injury process.[209] Several studies supporting the concept of resolving
edema as an explanation for WMH regression are based on observations in both CADASIL
and stroke patients.[210] If this possibility were responsible WMH regression, one would
expect that measures of atrophy would increase in the setting of WMH regression as
inflammatory edema resolved, and that cognitive function would improve. Although this
is a possibility for some WMH lesions, the overall lack of increased atrophy argues against
this mechanism as a primary determinant of WMH regression.
Lastly, it is possible that WMH regression is most closely related to resolution of
reversible ischemic changes or to healing or regenerative processes after such injury. In
such a scenario, WMH regression would be associated with either no change or increased
brain volume, and would also be associated with improvement in cognitive test
performance. This pattern of association is exactly what is seen in the present study,
supporting this hypothesis.
Our data highlight the importance of considering WMH change over time as a
dynamic process which can be related to both positive and negative structural and cognitive
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outcomes. The clinical implications of our findings could have a significant impact as we
begin to explore the many demographic, risk and treatment variables that may have
influenced longitudinal WMH change in our cohort of subjects. Much work is needed to
identify associations that may serve as fertile ground for exploration of disease modifying
strategies in vascular cognitive impairment and dementia.
This study does have limitations. The ADNI cohort has unique characteristics
based on its inclusion/exclusion criteria which include an emphasis on earlier staged
disease including normal and MCI subjects as well as criteria that excludes those with
significant cerebrovascular disease and/or CVD risk factors. As such, the cohort may not
be generalizable to epidemiologic and community-based cohorts that may have higher
proportions of cognitively impaired individuals and/or those with increased
cerebrovascular risk factors and/or WMH burden. Further, we used global net change in
the WMH between the baseline and the follow up visits, limiting our ability to detect
regional change in WMH progression, stability or regression compared to more detailed
spatial location analyses used by others previously.[202]
Despite these limitations, the present study allowed an exploration of cognitive and
brain volume changes that are associated with dynamic WMH change in a straightforward,
easily-interpretable fashion. The present data demonstrate that WMH regression is not a
mere imaging artifact or artifact due to methodologic procedures, but rather represents an
actual biological phenomenon that may, at least in part, reflect recovery from and
resolution of reversible cerebrovascular injury. The present findings demonstrating that
WMH and cSVD are potentially reversible processes is not only intriguing, but also lays
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the foundation for future interventional studies for subcortical vascular dementia as a
highly prevalent cause of cognitive decline and dementia in the aging population.
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CHAPTER 5. CONCLUSION
5.1 Overview:
This purpose of these studies was to examine novel ways in which conventional
MRI scans can identify the relative contributions of AD & cSVD to GCA and WMH in
order to generate new biomarkers & insights that might prove useful in the detection of
both “pure” and mixed disease states.
To do so, we first examined the relationship of cSVD visualized as WMH on
FLAIR imaging in relation to GCA. Our data clearly demonstrate that WMH are more
strongly associated with GCA, than CSF Aβ levels. The clinical importance of this finding
should not be understated. Frequently when clinicians see extensive GCA, AD moves to
the top of the differential diagnosis. This often leads to an under diagnosis of cSVD, and
potentially the development of therapeutic interventions which may miss the target in
regards to either reducing the rate of cognitive and functional decline or potentially halting
the progression of clinical disease. In other words, when a clinician encounters a patient
with significant GCA on MRI imaging, they should carefully examine for the presence of
WMH, which if found, should direct them to begin to target CVD risks rather than simply
attribute the GCA to AD pathology.
Second, we sought to investigate the association of the CSF Aβ (a surrogate
biomarker of AD) with the WMH seen on FLAIR imaging. Specifically, we sought to
determine if the WMH associated with AD vs. cSVD were spatially distinct. The findings
from this 2nd study clearly demonstrate that WMH reflect contributions of both AD and
cSVD processes that represent distinct, additive pathologic processes rather than a
synergistic interplay between these disease entities that contribute to the eventual
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development of dementia. Specifically, our data demonstrates that WMH located in the
parietal and occipital periventricular region are strongly associated with CSF Aβ 1-42
levels. On the other hand, WMH in the deep frontal regions were more likely to be
associated with HTN, suggesting cSVD as the underlying pathology for such findings.
Finally, we sought to determine if WMH change overtime was static, progressive and/or
potentially reversible in regards to pathologic etiology through an examination of the
association of WMH progression or regression with the CSF Aβ, Tau and Amyloid PET
(surrogates of AD). Our data clearly demonstrate that WMH are highly dynamic with many
cases demonstrating regression of the WMH that appear to be largely driven by control of
CVR (specifically HTN in our cohort) rather than AD, which consistently appears to lead
to WMH progression rather than regression.
These findings suggest that MRI may represent a low cost non-invasive marker for
both AD and cSVD that could prove useful in teasing out the relative contributions of these
specific etiologies in cases representing mixed pathological disease states. These findings
have broad implications for the development of effective therapeutic interventions for
individuals in regards to primary prevention for asymptomatic individuals, secondary
prevention for those in the earliest of clinical stages of cognitive decline, and further for
halting and/or possibly reversing dementia progression, at least in those with a strong
component of cSVD pathology.

5.2 HTN as the Major CVR Associated with cSVD:
The effect of HTN on the brain are mediated by many factors including patient
specific characteristics, time at which the diagnosis of HTN was made, duration of disease,
the degree of blood pressure elevation and severity of the disease. Chronic, uncontrolled
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HTN has been shown to lead to thickening of cerebral blood vessels’ basement membranes,
reducing cerebral blood flow,[211] which may greatly accelerate the pathophysiological
development of both AD and VaD.[212] In addition, uncontrolled HTN almost universally
leads to cSVD, manifest as white matter rarefaction, widening of perivascular spaces,
cerebral microbleeds, and overt ischemic infarcts.[213] cSVD can occur in conjunction
with comorbid AD or can be the sole cause of cognitive decline and dementia in many
cases.
Uncontrolled midlife HTN has been found to increase dementia risk in older adults,
Suggesting that targeting HTN earlier in midlife may help reduce the incidence and
prevalence of late the life cognitive dysfunction and dementia.[214] In addition, the
Honolulu Asia Aging study (n = 7878), reported that 27% of patients with midlife HTN
and 17% of patients with pre HTN, go on to develop late life cognitive decline.[215] The
influence of uncontrolled HTN on the development of dementia of both the AD and cSVD
type appears clear from the current literature and yet the fact that many cases of both AD
and cSVD exist suggest that HTN is neither necessary nor sufficient to explain all cases of
dementia and the interplay between these complex pathologic disorders.
Treatment of HTN represents an additional confound in our understanding of the
complexity of the relationship between vascular pathology and AD.[212] It is clear from
many studies that appropriate management of HTN can reduce the risk of late life cognitive
decline and dementia. Results from the Honolulu Asia Aging Study suggest that
antihypertensive treatment with a beta blocker is superior to the use of any other
antihypertensive medicine in decreasing the risk of incidental cognitive impairment.[216]
Yet other studies have suggested that dementia risk reduction related to the management
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of HTN is not specific to the type of antihypertensive used, and that benefits can be seen
with any anti-hypertensive therapy including diuretics, calcium channel antagonists,
angiotensin receptor blockers and angiotensin-converting enzyme inhibitors, in addition to
beta blockers.[217]
In contrast to midlife HTN, late-life HTN has not been found to be associated with
cognitive decline. In fact, the opposite may be true, with some studies demonstrating an
association between the late life low systolic blood pressure and cognitive decline in
elderly.[218] The Rotterdam and the Gothenburg studies reported that lower diastolic
blood pressure in late-life was associated with increased risk of both cSVD and AD,
especially among the users of antihypertensive medications.[219] In contrast, the Bronx
Aging Study found that low diastolic blood pressure was associated with AD whereas the
effect of low systolic blood pressure was inconsequential.[220] Yet other studies have
suggested that the association of late-life hypotension and dementia risk exists for both
systolic and diastolic hypotension.[221] Still others have reported that both mid and late
life blood pressure may act in conjunction to increase the risk of dementia with lower latelife diastolic pressure and midlife HTN acting in conjunction in the development of late
life dementia.[222]
The data presented demonstrates that a history of hypertension is strongly
associated with baseline WMH volumes. In addition, the Δ change in SBP over a period of
one year is significantly associated with the Δ change in WMH volumes. These results are
in line with findings from the existing, published literature, supporting our hypothesis that
lowering SBP may lead to regression of WMH lesion volumes and an overall decrease in
WMH burden overtime.[223]
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5.3 AD Conventional Biomarkers:
5.3.1 Imaging Markers:
T1-weighted MPRAGE imaging sequences can evaluate changes in cortical sulci
volume (cross-sectionally) and atrophy (longitudinally) in hippocampus, parahippocampal
gyrus, entorhinal cortex, posterior cortex, subcortical nuclei and amygdala, which are
affected early in the course of disease for AD patients.[67, 68] T1-weighted sequences in
particular, can aid the clinician and researcher in estimating MTA as an early neuroimaging
marker of AD.[69] Semi-quantitative visual rating scales such as the Scheltens’ scale, can
be easily taught and assessed with routine clinical imaging in either two-dimensional or 3dimensional sequences.[70] Evaluation of MTA is best performed in the coronal plane
which allows more accurate visualization of medial temporal lobe volumes that are not
affected by tangential slicing of these structures as can occur with axial and/or sagittal
acquisitions in addition there are a number of automated and semi-automated post
acquisition processing software packages that can provide voxel by voxel volumes
allowing quantitative assessment of these and other discrete structures within the brain.
Using T1-weighted sequences in the diagnosis of AD is practical as it is non-invasive,
relatively inexpensive, recommended currently as part of the practice parameter for a
valuation of memory loss and dementia, and is almost universally covered by all insurance
and other third-party payers compared to the other imaging modalities.
Amyloid PET can be useful in differentiating dementia such as AD from other
forms of dementia that do not include amyloid deposition as a pathologic feature such as
Frontotemporal Dementia (FTD).[83, 84] The specificity of amyloid PET scans for
Alzheimer’s disease is low and positive scans are also frequently seen in cases of Dementia
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with Lewy Bodies (DLB).[85, 86] Despite its limitations, Amyloid PET has been widely
used to detect the pre-clinical stage of AD,[89] which has opened up new possibilities for
secondary prevention trials in the area of AD. In addition, it is important to note that unlike
CSF Aβ, Amyloid PET scans can detect the neuroanatomic extent and distribution of
amyloid deposition.[224] However, it should be noted that amyloid PET scans are
expensive and often not covered by insurance and other third-party payers.
fMRI is another imaging modality that being used for the diagnosis of early stages
of AD. BOLD can demonstrate abnormalities in the hippocampus, inferior parietal lobe,
medial temporal lobe and cingulate cortex in AD that may provide clues to a pure and/or
mixed state.[90, 91] Exploration of fMRI is led to many contradictory findings however
and was not included as a methodology examined in the current set of experiments.
5.3.2 CSF Aβ:
Parenchymal and vascular deposition of Aβ occurs very early in the course of
AD.[225] Aβ deposition can result in an increased thickening of blood vessels’ wall,
vascular tone, vasoconstriction, and reduced cerebral blood flow,[226] eventually resulting
in cerebral ischemia and the development of WMH. Cerebral Amyloid Angiopathy (CAA),
characterized by the accumulation of Aβ protein in the walls of small-medium sized blood
vessels and capillaries may be an important contributor to deficits in nutrient and oxygen
exchange as well as to resultant tissue injury occurring at the microvascular level.[13] CAA
can also be associated with intracerebral hemorrhage, WMH, and cSVD, in addition to
Alzheimer’s disease.[28, 29]
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It is important to note that CSF Aβ is being widely used for the diagnosis of AD,
however, this procedure carries a more than minimal risk to the patients as it is considered
an invasive procedure. In this thesis, we chose to examine whether or not noninvasive MRI
could prove useful for the diagnosis of AD in regards to WMH volume and distribution
that could in many cases supplant or be used as an alternative diagnostic modality for AD.

5.4 Imaging Markers Used in the Current Study:
As discussed in detail in this dissertation, many imaging markers can be reliably
used to diagnose AD, cSVD or both. We used well validated MRI structural and injuryassociated imaging markers, including T1-weighted and FLAIR sequences. Both
sequences were analyzed using simple visual rating scales such as the Scheltens scale for
the MTA, Fazekas scale for the WMH and the Pasquier scale for the GCA. In addition, we
performed more sophisticated volumetric measures using the T1-weighted and the FLAIR
images to quantify the WMH and further determine the differences in the spatial
distribution of the WMH associated with AD vs. cSVD.
Using these MRI biomarkers in novel ways to address our hypotheses prove their
utility in diagnosis and differentiation of underlying AD and cSVD pathology. Using MRI
in this fashion overcomes many of the impediments to routine biomarker diagnosis of AD
and mixed pathologic disease states as it is considered relatively cheap and non-invasive
when compared to the more expensive imaging modalities such as Amyloid PET and Tau
PET scans and to more invasive procedures such as a spinal tap to collect CSF biomarkers.
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5.5 cSVD is a Greater Contributor to GCA than AD:
Our data demonstrates that moderate to severe GCA seen on brain imaging studies
should not be solely attributed to normal aging or AD. Instead, cSVD should be considered
as the proximate cause of moderate-to-severe GCA in the majority of cases. Such
understanding may help direct appropriate diagnosis and treatment strategies for those
undergoing evaluation of memory complaints or more significant cognitive decline that
have had structural imaging performed as part of the diagnostic workup.

5.6 AD and HTN are Associated with Spatially Distinct WMH:
Our study demonstrates that the effects of HTN and CSF Aβ1-42 levels on WM
injury may be additive rather than synergistic, with each associated with distinct spatial
distributions of WMH. Considering such spatial distributions during routine diagnostic
evaluation may improve diagnostic accuracy and further contribute to optimal development
of treatment paradigms that address cSVD and AD, either separately or in combination.
The present studies remain largely empiric and on the basis of our data it remains unclear
as to whether the underlying pathophysiology and mechanisms of cerebral injury manifest
as WMH are the same in the different brain regions identified as being independently
associated with either AD or cSVD.

5.7 WMH are Dynamic with AD Participants Being More Likely to Progress:
Results from the third experiment in this thesis demonstrate that WMH regression
is associated with decreased brain atrophy and improvement in memory performance over
a period of 2-years compared to participants with progressive WMH changes (Figure 5.1).
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There are several potential explanations for the WMH regression seen in this
cohort. First, ischemic non reversible injury, may regress due to the process of gliotic
contraction and micro- and or macroscopic encephalomalacia. In this setting one would
expect increasing brain atrophy (due to encephalomalacia) in the follow up scan, but as the
injury is static, one would expect no change in cognitive performance (Figure 5.2). Second,
inflammation that is associated with irreversible ischemic injury, leading to WMH
regression as a result of resolution of the inflammation and edema with restoration of
normal function in the resolved inflammatory penumbra. If such an explanation were true,
one would expect to see an increase in brain atrophy secondary to reduced inflammatory
edema in such cases. However, we would expect some improvement in cognitive
performance as a result of resolution of the inflammatory penumbra (Figure 5.2). Finally,
it is possible that WMH regression could be the result of a healing or reparative process of
ischemic injury. If such were true, one would expect to see reduced brain atrophy (no
gliotic contraction or encephalomalacia in restored tissue) and improvement in the
cognitive performance as a result of this healing process (Figure 5.2). The latter explanation
may in part explain the characteristics associated with WMH regression seen in experiment
#3 using the ADNI II cohort.
It is important to note that WMH regression was not associated with the CSF Aβ or
Amyloid PET measures, suggesting that WMH regression may be primarily driven by CVR
rather than AD processes. This observation suggests that aggressive management of SBP
may be a possible target for future clinical trials to reduce the WMH burden and dementia
that may exist independent of AD processes. In contrast, our data suggest that WMH
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Figure 5.1 Descriptive figure showing the dynamic nature of the white matter
hyperintensity changes overtime and the associated change in brain volume and cognitive
performance.

The battery represents the memory performance. The upper row is showing a
representation of how the white matter hyperintensity (WMH) remains stable in the follow
up visit. Similarly, brain volume and memory remained stable in the follow up visit as
shown in A2 and A3. The middle row is showing the progression of WMH over time. In
B3 note how the WMH lesion is growing, the brain volume is remarkably reduced and the
memory is getting worse compared to B2. Finally, the lower row is showing a
representation of a WMH regression over time. In C3 note how the WMH lesion is
shrinking, the brain volume is maintained or even minimally increase, and the memory is
improving when compared to C2.
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Figure 5.2 Decsriptive figure showing the possible mechanisms that lead to white matter
hyperintensity regression overtime and their associated effect on the brain volume and the
cognitive performance.

The battery represents the memory performance. The upper row is showing the first
potential mechanism of white matter hyperintensity (WMH) regression, which is the
ischemic non reversible injury. In A3 note how the WMH lesion contract (black arrows)
and the brain volume is reducing when compared to A2. However, the memory
performance did not change when compared to A2. The middle row is showing how
inflammation as a potential cause of WMH regression. In B3 note that the lesion is
shrinking, the brain volume is reducing and the memory is improving a little bit when
compared to B2. Note that the difference between A3 and B3 is in memory performance.
Finally, the lower row represents the third possible explanation of WMH regression, which
is the most likely cause in our study. In C3 note that the WMH lesion is regressing, the
brain volume and memory performance is increasing when compared to C2. Note that the
difference between C3 and B3 is in the brain atrophy in which the latter showed more
atrophy.
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associated with AD processes are irreversible at present and almost universally will
progress until such time as effective disease modifying therapies for AD are developed.
In support of this contention, participants with progressive WMH changes
demonstrated increased atrophy, poorer memory performance, higher tau/Aβ and more
temporal lobe amyloid deposition again attesting to an unrelenting AD pathologic
progression (Figure 5.1). Irrespective of whether WMH progression is due to AD processes
or to uncontrolled SBP, our data clearly demonstrate that WMH progression is associated
with worsening memory [203-205] and greater brain atrophy.[126]

5.8 Overall Conclusion:
These data demonstrate that both AD and cSVD frequently coexist in the same
brain, contributing differentially to alterations in brain structure, subcortical white matter
injury, and cognitive function. These effects can be disentangled using MRI, and while we
currently lack therapeutic interventions to halt or reverse AD, the dynamic WMH change
evident in our data clearly suggests that the ability to reverse cSVD exists today.

5.9 Future Planned Studies:
Ongoing studies in these cohorts include an assessment of CVR and the relationship
of specific CVD risks with the development and/or progression of WMH. In addition, our
lab is actively exploring WMH change over time at the voxel level “WMH penumbra.”
This work is being done in collaboration with Ahmed Bahrani (a PhD candidate in
biomedical engineering at the University of Kentucky). In brief, WMH penumbra
represents areas of dynamic WMH changes over time. The penumbra surrounding the
WMH core can be identified using FLAIR, diffusion tensor imaging (DTI) and arterial spin
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labeling ASL sequences on MRI. While several groups have postulated the existence of a
penumbra and we were able to demonstrate abnormalities in DTI and ASL in a proximal
tissue sphere around WMH, we are the first to develop a precise WMH penumbra detection
protocol using FLAIR images. This experiment is in its final phases and may potentially
change our fundamental understanding of the WMH Penumbra phenomenon.
Further studies are needed to explore whether the distinct spatial patterns of WM
alteration seen as a result of AD and or cSVD are associated with impairment of different
cognitive processes, longitudinal clinical progression, and/or clinical outcomes. These data
are also being used to further explore the development of an algorithmic, novel, noninvasive, neuroimaging marker for AD that includes previously identified structural
determinations of medial temporal lobe and discrete cortical regional atrophy in
conjunction with or novel WMH distribution patterns that are linked to Alzheimer’s disease
derived from experiment #2. The potential validation of such a biomarker algorithm may
not only prove extremely useful for clinicians that currently lack inexpensive and
noninvasive biomarkers for use in the routine clinical setting, but may also prove extremely
cost-effective in identifying amyloid positive participants, irrespective of cognitive status,
for participation in the burgeoning number of clinical trials for AD that are currently
limited universally by an inability to reliably and cheaply identify those at risk.
Cumulative data from the experiments that comprise this thesis are also being used
to help design early interventional trials in the area of cSVD. Such trials are focused on
modulation of hypertension and exploration of biological change in WMH volume and
distribution that will lead to more efficient clinical trials requiring fewer subjects, and less
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invasive and costly means of determining pharmacodynamic effects of intervention than
those currently available.
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